Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download National Cancer Intelligence Network Cancer Outcomes Conference
Transcript
PROGRAMME AT A GLANCE DAY ONE – MONDAY 8 JUNE Grand Ballroom Conference Registration, Posters & Exhibition Viewing 11:00 – 12:30 Exhibition Centre Welcome & Plenary Session 1: Changing clinical practice: Importance of routine data and cancer registries 12:30 – 13:50 13:15 – 13:30 Grand Ballroom Dublin 1&2 Lunch - Exhibition & Poster Viewing Cancer Patient Portal demonstration 13:50 – 15:20 Session 1 Session 2 Session 3 15:20 – 15:50 Exhibition Centre Penthouse Suite Dublin 1&2 Grand Ballroom Parallel Sessions Early Diagnosis of Cancer Data Processing, Management & National SACT data Treatments Refreshments, Exhibition & Poster Viewing 15:50 – 17:20 Exhibition Centre DAY TWO – TUESDAY 9 JUNE Plenary Session 2: Role of Primary Care in Cancer Prevention, Screening and Early Diagnosis 08:00 – 08:45 Grand Ballroom Conference Registration, Exhibition & Poster Viewing 08:45 – 10:30 Exhibition Centre Plenary Session 3: International issues in cancer 10:30 – 11:00 Grand Ballroom Refreshments, Exhibition & Poster Viewing Exhibition Centre Penthouse Suite Dublin 1&2 Grand Ballroom Library Bar Parallel Sessions Changing Clinical Practice Prevention Childhood, Teenage & Young Adults Lunch - Exhibition & Poster Viewing CRUK Dragon’s Den (pre-booking required) 14:00 – 15:30 Session 7 Session 8 Session 9 15:30 – 16:00 Dublin 1&2 Exhibition Centre Penthouse Suite Grand Ballroom Parallel Sessions Site Specific Clinical Reference Group– Urology Cancers Survivorship Epidemiology/Clinical trials Refreshments, Exhibition & Poster Viewing 16:00 – 17:30 Exhibition Centre 11:00 – 12:30 Session 4 Session 5 Session 6 12:30 – 14:00 Plenary Session 4: Childhood, Teenage and Young Adult Cancers, Beyond Cancer Survival National Cancer Intelligence Network Cancer Outcomes Conference 2015 National Cancer Intelligence Network : Cancer Outcomes Conference 2015 09:30 – 11:00 Carrick-a-Rede Rope Bridge City Hall Giant’s Causeway DAY THREE – WEDNESDAY 10 JUNE 08:30 – 09:30 Grand Ballroom Library Bar Conference Registration, Exhibition & Viewing Poster Finalists AGM of UK & Ireland Association of Cancer Registries 09:30 – 11:00 Session 10 Session 11 Session 12 11:00 – 11:30 Dublin 1&2 Penthouse Suite Exhibition Centre Grand Ballroom Parallel Sessions Pharmaco-Epidemiology Health Economics Inequalities Refreshments, Exhibition & Viewing Poster Finalists 11:30 – 12:40 Exhibition Centre Plenary Session 5: Panel Debate: Future challenges for cancer services 12:40 – 13:00 Exhibition Centre Poster Prizes & Close of Conference 13:00 – 14:00 Grand Ballroom Lunch (packed lunch available on request, must be pre-booked) 8-10 June | Europa Hotel, Belfast Contents Venue Map........................................................................................................................... 2 Welcome to the Conference.............................................................................................. 4 Scientific Committee and Thanks...................................................................................... 5 Conference Sponsors.......................................................................................................... 6 Conference Exhibitors....................................................................................................... 14 Conference and Venue Information................................................................................. 17 Poster Information............................................................................................................. 22 Speaker Information.......................................................................................................... 23 UKIACR Annual General Meeting................................................................................... 25 Programme: Monday 8 June.......................................................................................... 26 Detailed Programme......................................................................................................... 27 Plenary Session 1............................................................................................................... 31 Plenary Session 2............................................................................................................... 33 Programme: Tuesday 9 June.......................................................................................... 35 Detailed Programme......................................................................................................... 36 Plenary Session 3............................................................................................................... 43 Plenary Session 4............................................................................................................... 45 Programme: Wednesday 10 June................................................................................. 48 Detailed Programme......................................................................................................... 49 Biographies........................................................................................................................ 52 Posters................................................................................................................................ 72 Notes...................................................................................................................................94 Venue Map Penthouse Suite th 12 Floor Dublin Suite & Copenhagen Suite nd 2 Floor Business Suite Grand Ballroom st 1 Floor Exhibition Centre & Registration Ground Floor 2 Belfast Map Belfast Map 3 Welcome to the Conference Belfast Map Welcome to the National Cancer Intelligence Network (NCIN) Cancer Outcomes Conference 2015: ‘United Against Cancer’ in association with the United Kingdom and Ireland Association of Cancer Registries (UKIACR) and the N. Ireland Cancer Registry (NICR). We offer you a programme of internationally acclaimed speakers on a wide range of topics from cancer prevention through early detection, treatment outcomes, survivorship issues and end of life care with sessions on health economics, pharmaco-epidemiology, cancer in children and young people and inequalities adding interest to the mix. Since its inception, the NCIN has had a remit to focus across the cancer agenda, from patients and carers to policy makers, and across the UK. So it is good to be in Belfast to celebrate 21 years of the N. Ireland Cancer Registry, and in particular to welcome almost 100 cancer patients and carers as active participants, thanks to bursaries from NCIN. We thank all our sponsors who have helped us provide what we hope will be an educational and enjoyable event. The Network, and its conferences, have always brought together the views and expertise of its members, especially patients and clinicians, to understand and update on the use and sharing of evidence to affect outcomes and inspire interventions that will make a difference to public health now and in the future. The Network has always sought to put patients and their views uppermost in how it operates, and we will be announcing a significant new initiative around patient empowerment during this conference. Throughout the conference, you will hear from speakers that are often ‘behind the headlines’. We encourage you to explore our poster and exhibitors and learn more about the strength and breadth of work being done throughout the UK and Ireland, using information to improve outcomes. Chris Carrigan, Head of the NCIN, Public Health England Anna Gavin, Director, N. Ireland Cancer Registry Julia Verne, Co-Chair UKIACR, Head of Epidemiology, Public Health England Forum Margaret Grayson, Chair, NI Cancer Research Consumer 4 Scientific Committee and Thanks Members of the Cancer Outcomes Conference Scientific Committee are: Anna Gavin – Chair Rachael Brannan David Brewster Chris Carrigan Harry Comber Nicky Coombes Margaret Grayson Dyfed Wyn Huws Yoryos Lyratzopoulos Mick Peake Richard Stephens Julia Verne James Wong The Scientific Committee would especially like to thank Abbey Conference & Events who were tasked with organising this year’s conference in Belfast. In particular Patricia McColgan, Anja Fischer and Danielle Devaney. The Scientific Committee would also like to acknowledge the N. Ireland Cancer Registry and their contribution to the planning and organising of the conference hosted in Belfast, especially Deirdre Fitzpatrick and Susan McGookin. 5 Sponsors The National Cancer Intelligence Network would like to thank our conference sponsors for their continued commitment to the Cancer Outcomes Conference and for their financial support. Sponsorship & Exhibition Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research. Our vision is to bring forward the day when all cancers are cured. We fund over 4,000 scientists, doctors and nurses, across all types of cancer. Our pioneering work into preventing, diagnosing and treating cancer has helped double UK survival rates in the last forty years. And our ambition is to see at least 3 in 4 patients survive cancer by 2034. Sponsorship Make the Visit Belfast Welcome Centre your first stop on coming to Belfast or contact us for information in advance of your stay. Located in the city centre with information on accommodation, visitor attractions, tours, events and transport within Belfast and Northern Ireland our staff are here to assist you in planning your visit. Tourism NI's Mission is to build the value of tourism to the local economy. Our Vision is to confidently and passionately champion the development and promotion of the Northern Ireland experience. Tourism NI is responsible for the development of tourism and the marketing of Northern Ireland as a tourist destination to domestic tourists, from within Northern Ireland, and to visitors from the Republic of Ireland. We are a non-departmental public body of the Department of Enterprise, Trade and Investment and we work closely with other tourism bodies to help develop the visitor economy here and to market Northern Ireland to incoming visitors. 6 Sponsors Sponsorship & Exhibition At Macmillan, we know a cancer diagnosis can affect every aspect of a person’s life. We support people throughout their cancer journey, helping them to make the choices needed to take back control. To achieve this we do more research into the needs and experiences of people living with cancer and their carers than any other charity in the UK. We work with a wide range of evidence, including routinely collected health data and patient-reported outcomes, and a variety of research partners, including the NCIN and several leading UK universities. As well as directly supporting people affected by cancer, we also develop services and policy solutions and build relationships across the health and social care sector to drive change. In the Survivorship session at this year’s NCIN conference, chaired by Macmillan’s Professor Jane Maher, you can learn more about one example of this work, our Transforming Cancer Follow-up Programme in Northern Ireland. To support our services and policy work, we are also committed to understanding the cost of cancer in the broadest sense. Our Cancer Population Evidence Programme has identified health economics as a vital discipline for addressing the challenges posed by a growing population of people living with cancer, as reflected by our sponsorship of the conference’s Health Economics session. The session includes a highlight of preliminary findings from Macmillan-funded research by Dr Mauro Laudicella, using patient-level data to put figures to the economic burden of cancer in England. Sponsorship The UK and Ireland Association of Cancer Registries (UKIACR) replaced the UK Association of Cancer Registries following the merging of the eight English Regional Cancer Registries to the National Cancer Registration Service. Membership now includes the National Cancer Registry of Ireland as a full member, (previously it had observer status) plus Scotland, Wales, Northern Ireland, England and the Office of National Statistics 7 Sponsors (ONS). Observer status remains with the National Cancer Intelligence Network (NCIN). There are also associate members, which include the major charities and the London School of Hygiene and Tropical Medicine. Dr Julia Verne (PHE) and Dr David Brewster (Scotland) are currently co-chairs of the UKIACR. The subgroups of the UKACR have been retained as their work is recognised as excellent for the standardisation and enhancement of cancer registration and the use of population-based cancer registry data. The subgroup chairs attend the UKIACR executive committee meetings The historic UKACR Conference has, since 2008, been linked with the National Cancer Intelligence Network (NCIN) conference, which is a larger event with a focus on inviting patients and policy makers. The UKIACR is also now associated with this in the same way as UKACR. Sponsorship CLIC Sargent is the UK’s leading cancer charity for children and young people, and their families. We provide emotional, practical, financial and clinical support to help them cope with cancer and get the most out of life. We are there from diagnosis onwards and aim to help the whole family deal with the impact of cancer and its treatment, life after treatment and, in some cases, bereavement. Sponsorship Teenage Cancer Trust was established in 1990, the charity is dedicated to improving the quality of life and outcomes for the seven young people aged between 13 and 24 diagnosed with cancer every day. We fund and build specialist units in NHS hospitals and provide dedicated expert staff and services, bringing young people together so they can be treated by teenage cancer experts in the best place dedicated to them. These investments are improving the experience and care of young people with cancer. With additional investment going into other initiatives such as the National Cancer Intelligence Network, National Cancer Research Institute and TYAC, the funding of 8 Sponsors research, lobbying for change in health policy, working collaboratively nationally and internationally, we strive to improve outcomes for young people. Over the next five years Teenage Cancer Trust will focus on maintaining current services and expanding them to supporting all you people, not just those treated at Principle Treatment Centres. The charity will also expand its activities around raising awareness of the signs of cancer and young peoples cancers. We want to see all young people have the option of accessing dedicated young adult cancer services and support. Sponsorship & Exhibition We are Cancer Fund for Children. Every week in Northern Ireland, three children, teenagers or young adults aged between 0-24 years old will be diagnosed with cancer. We understand the devastating impact a cancer diagnosis and treatment can have on the whole family and that beyond the essential clinical care there is a family life that needs to be rebuilt both at home and in the community. As the leading local charity for children and young people with cancer, Cancer Fund for Children provides a range of specialist therapeutic support throughout Northern Ireland. Our team of Specialists is here to listen and help families cope with the impact cancer has on their lives. Sponsorship Cancer Focus Northern Ireland is a local cancer charity working since 1969 to reduce the impact of cancer on peoples’ lives. We provide care and support services for cancer patients and their families; offer a range of cancer prevention programmes to help people lessen their risk of getting cancer; fund scientific research into the causes and treatment of the disease and campaign for better health policy to protect our community and its future. 9 Sponsors Sponsorship Men deserve better. It’s that simple. That’s why we’ve invested millions of pounds into research, services and awareness over the last ten years. It’s the reason we provide services to men and their families like our Specialist Nurses, one-to-one support and information leaflets. It’s why we’re leading the way in providing prostate education to medical professionals. It’s why we don’t take no for an answer when it comes to fighting our campaigns. We are Prostate Cancer UK. Donation The Irish Cancer Society is the national cancer charity providing information, support and care to those with and affected by cancer in Ireland. We are working to educate the public on how to reduce their risk of cancer, to support those living with cancer and to advance research to find better ways of diagnosing and treating cancer. The Society is also working at a public policy level, lobbying for policies and legislation which we believe can save lives. At the Irish Cancer Society, we won’t give up until cancer does. Sponsorship The Health and Social Care Research and Development (HSC R&D) Division is part of the Public Health Agency, however its function predates the Agency as it was set up in 1998 by DHSSPS to support R&D in Health & Social Care in Northern Ireland. Its work is based on the principle that the best health and social care must be underpinned by knowledge, based on well conducted research, which can then be applied in the delivery of care. The HSC R&D Division supports researchers based in Northern Ireland as well as those in Health and Social Care Trusts or other bodies who use the outputs from research findings. While the effectiveness of research performance and application depends ultimately on the skill and ability of individual researchers and users of research, the HSC R&D Division ensures that researchers can work within an environment that supports, encourages and facilitates them. Further information on the work of HSC R&D Division can be found on the website: www.research.hscni.net 10 Sponsors Sponsorship Action Cancer is one of Northern Ireland’s leading local cancer charities. The charity provides early detection of cancer through breast screening, screening some 10,000 women annually between the ages of 40 to 49 and 70+. This unique service is available at Action Cancer House Belfast and from its state of the art “Big Bus” that travels to over 225 locations across the country. The charity also provides from 10 different locations support services to anyone affected by a diagnosis of cancer, including children and families. Supports include, counselling, life coaching, peer support, complementary therapies and acupuncture. It also delivers extensive cancer prevention, health promotion and education programs including health checks and healthy living activities. Sponsorship As patients interact with services in different care settings on a regular basis, it is critical that their clinicians are able to access accurate, up-to-date information to ensure the quality of care they receive. At InterSystems we join up health and care providers giving them a consolidated view of all the data upon which to make the best decisions. Within a hospital, community, registry, region or nation, our health informatics systems - including oncology - are enabling our clients to gain the benefits of connected health – better patient outcomes and cost management. InterSystems.co.uk 11 Sponsors Supported by: Titanic Belfast is a monument to Belfast’s maritime heritage. Today Titanic Belfast tells the stories of the ill-fated Titanic after she hit an iceberg and sank during her maiden voyage in 1912. The building contains more than 12,000 square metres of floor space, most of which is occupied by a series of galleries, private function rooms and community facilities. The Conference Dinner will be held in this impressive venue on June 9th and promises to be a memorable evening. The Welcome Reception on June 8th will be held in Belfast City Hall and we would like to thank Belfast City Council for their generous support of this evening. The N. Ireland Cancer Registry is hosted by Queen’s University Belfast, within the Centre for Public Health. Queen's University Belfast was founded as Queen’s College in 1845, before becoming a university in its own right in 1908. It is the ninth oldest university in the UK. Today, it is an international centre of research and education and a major part of the fabric of Northern Ireland. Queen’s is in the top one per cent of global universities and is a member of the Russell Group of 24 leading UK research-intensive universities. 12 Sponsors The N. Ireland Cancer Registry was established in May 1994 replacing an older incomplete registry and this conference celebrates 21 years of full population based cancer registration in N. Ireland. The registry is located in the Centre for Public Health, Queen's University Belfast and is funded by the Public Health Agency for Northern Ireland. It has strong links with service users having patient representation on the Council and involves patients and their representatives in the development of reports and their launch. The Privacy Advisory Committee for Northern Ireland which advises on patient confidentiality has commended the Registry on its work in this area. The Registry works closely with the local cancer charities, DHSS, the Public Health Agency and Trusts. The N. Ireland Cancer Registry is the official producer of cancer incidence and survival statistics in Northern Ireland and has published many reports on cancers in the population including the most recent Cancer incidence trends 1993-2013 with projections to 2020 and 2035 "Dying of Cancer - Perspectives of Bereaved Relatives and Friends" launched May 2015 and available on the registry website www.qub.ac.uk/NICR 13 Exhibitors The exhibition at the Cancer Outcomes Conference 2015 will run each day during the conference. Chameleon Information Management Services Ltd (CIMS) is an information company specialising in the implementation and support of InfoFlex software. InfoFlex is used extensively across the NHS to support the national cancer reporting requirements as well as the day-to-day cancer patient management. InfoFlex supports all aspects of Cancer data collection and meets all national reporting requirements. This includes the latest COSD data collection and XML reporting requirements, MacMillan Treatment Summaries, SACT, Holistic Needs Assessments, support of CNS and Remote Monitoring. InfoFlex provides a single fully integrated patient care-pathway solution that can be easily extended to cover other elements of the patient care-pathway and research. Contact CIMS on 01923 896939 or www.infloflex-cims.co.uk National Cancer Research Institute (NCRI) is a partnership between the major cancer research funders in the UK. We promote cooperation in cancer research in response to areas of need and opportunity. Through our initiatives and the NCRI Cancer Conference, we encourage knowledge sharing and cross-disciplinary collaboration for the benefit of patients, the public and the research community. Come and visit our exhibition stand to find out more about us and our work. www.ncri.org.uk 14 Exhibitors Public Health England (PHE) exists to protect and improve the nation's health and wellbeing, and reduce health inequalities. It does this through world-class science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. PHE is an operationally autonomous executive agency of the Department of Health. Public Health Wales exists to protect and improve health and wellbeing and reduce health inequalities for people in Wales. We are part of the NHS and report to the Minister for Health and Social Services in the Welsh Government. Our vision is for a healthier, happier and fairer Wales. We work locally, nationally and, with partners, across communities in: • • • • • • • • • • Health protection Microbiology Screening NHS quality improvement and patient safety Health improvement Primary, community and integrated care Safeguarding Health intelligence Policy, research and international development inequalities for people in Wales. The Welsh Cancer Intelligence and Surveillance Unit is part of the Health Intelligence and Knowledge Management Division. The unit carries out the statutory duty of the systematic collection, analysis and dissemination of information about the health of the people of Wales in particular including cancer incidence, mortality and survival. 15 Exhibitors Pancreatic Cancer Research Fund is the UK charity dedicated solely to beating pancreatic cancer through research. With a 3% survival rate, more research is vital. We fund world-class research projects at institutions around the UK and Ireland, to advance more effective detection, diagnosis and treatment. To date thirty-four projects have been funded, with a total value of £5.2 million. Independent Cancer Patients Voice believes that patients should be active participants in cancer research and treatment rather than passive recipients of care. ICPV provides education, mentoring and support for people who, having been treated for cancer, want to add an effective patient perspective to cancer research. Our new Science for Advocates five day course is a “global first” as it includes lab- based experience as well as lectures and discussion. We can offer researchers access to advocates who are confident, informed and realistic lay partners in research offering constructive criticism and advice leading to improved recruitment. InstantAtlas, from GeoWise, is an easy to use interactive mapping software that helps information analysts and researchers create highly-interactive dynamic and profile reports. By combining statistics and map data InstantAtlas enhances communication and engages people in more informed decision making. InstantAtlas is being used by organisations worldwide to disseminate public health data such as: cancer incidence rates, diabetes, mental health and obesity. The GeoWise team has a unique blend of skills in design, programming, geography and statistics. GeoWise was formed in 1997 and is based in Edinburgh in the United Kingdom. 16 Conference and Venue Information Conference programme, abstracts, slides and posters This booklet contains outline information about the conference programme. To see the abstracts of the poster presentations please check the conference website: http://www.qub.ac.uk/NCIN2015/. Only the titles are included in this booklet. Most slide presentations will be available in PDF format on the conference website after the event (subject to permission from the authors). PDFs of many of the posters will be added too. Registration and enquiries desk To collect your badge and conference booklet, or to speak to a member of our conference team with any enquiries during the event, please visit our registration desk, which is situated in the foyer area of the Exhibition Centre in the Europa Hotel. Accessibility If you require assistance please visit the conference registration desk and we will be happy to help. Badges Please make sure you wear your badge throughout the conference – without it you will not be able to get into the conference sessions and meals. If you lose your badge, please visit the conference registration desk. Places in sessions There is limited capacity in the parallel sessions and pre-booking was required. Once capacity is reached, for health and safety reasons, we will not be able to allow additional people into the room so please arrive in good time before the start of the session. Please help colleagues by avoiding sitting at the end of a row and leaving empty seats inaccessible. For those arriving after the session has started, kindly wait until the speaker has finished before taking a seat. 17 Conference and Venue Information Mobile devices As a courtesy to speakers and colleagues, please remember to switch mobile phones off or to silent during sessions. If you are presenting please do not have a mobile or pager on you when you are near the microphones. Wi-Fi Wi-Fi is free in the public areas of the hotel and in the conference rooms. If you wish to use the Wi-Fi, please choose the network “Europa Public Wi-Fi”. The password for this network is “Open2015”. Social media The Twitter hashtag for the Cancer Outcomes Conference is #NCIN2015. We would be delighted to have a lively stream of tweets during the conference. Poster exhibition Posters are displayed in the Grand Ballroom and may be viewed at the following times: Monday 8 June 09:30 - 11:00 12:30 - 13:50 15:20 - 15:50 Tuesday 9 June 08:00 - 08:45 10:30 - 11:00 12:30 - 14:00 15:30 – 16:00 Wednesday 10 June 08:30 – 09:30 11:00 – 11:30 Welcome Reception and Conference Dinner The Welcome Reception will take place on Monday 8 June at 18:45 in Belfast City Hall which is easy walking distance from the Europa Hotel. The Conference Dinner will take place on Tuesday 9 June at 19:00 at Titanic Belfast. Buses depart at 18:30 at the side entrance of the Europa Hotel (Glengall Street). Both events are by pre-booking, please remember to bring your tickets for admission. Evaluation of the conference We value your feedback about the Cancer Outcomes Conference 2015. Please complete the online evaluation which we will send to you after the conference. 18 Conference and Venue Information Photographs We will be taking photographs during the conference. If you do not wish to be included in this, please see the photographer. A selection of photographs will be uploaded to the conference website after the conference. In addition Macmillan Cancer Support will provide an exciting opportunity for delegates to have their picture taken at the gala dinner in Titanic Belfast (from 19:00-20:00). This is a fundraising event and a cost of £5.00 per picture will apply. CPD/Certificates of attendance Certificates of Attendance will be sent to you by email after you have completed the online evaluation. The conference has been accredited for 15 CPD points by the Royal College of Physicians. In order to receive your CPD points please ensure you sign in every day at the registration desk. Points vary according to the days you attend. Accommodation If you booked accommodation, you may be required to give credit card details to hotel staff at check-in to cover any incidentals. Your room key will be available for collection from the reception from 15.00 onwards. Breakfast (Europa Hotel) Continental Breakfast is available from 06.30, full breakfast from 07:00 in the hotel restaurant. Check out (Europa Hotel) Please check out of your room prior to the start of the conference on the day of your departure, hand your key card into the hotel reception, pay for any extras incurred and store your luggage in the luggage room located beside the registration desk. Liability The NCIN 2015 Conference and the Europa Hotel accept no liability for loss or damage to articles during the event. Car parking (Europa Hotel) Concierge will park cars for guests in McCauslands Carpark on the Grosvenor Road. As this is not the hotel carpark there is a charge of £16.00 per 24 hours parking. If you wish to use this service please contact concierge on your arrival. 19 Conference and Venue Information Airport shuttle to and from the Europa hotel A bus service runs from both Belfast City and Belfast International Airport and will drop you off at the Belfast Europa Buscentre which is adjacent to the Europa Hotel. For more information contact Translink on 02890 666630 or visit their website www.translink.co.uk. Room Locations Europa Hotel Registration & Plenary Sessions – Exhibition Centre – Ground Floor Parallel Sessions as follows: • Parallel Session 1 – Exhibition Centre (Main Plenary Room) – Ground Floor • Parallel Session 2 – Penthouse Suite – 12th Floor • Parallel Session 3 – Dublin 1&2 – 2nd Floor • Parallel Session 4 – Exhibition Centre (Main Plenary Room) – Ground Floor • Parallel Session 5 – Penthouse Suite – 12th Floor • Parallel Session 6 – Dublin 1&2 – 2nd Floor • Parallel Session 7 – Dublin 1&2 – 2nd Floor • Parallel Session 8 – Exhibition Centre (Main Plenary Room) – Ground Floor • Parallel Session 9 – Penthouse Suite – 12th Floor • Parallel Session 10 – Dublin 1&2 – 2nd Floor • Parallel Session 11 – Penthouse Suite – 12th Floor • Parallel Session 12 – Exhibition Centre (Main Plenary Room) – Ground Floor Refreshments, Exhibition and Poster Viewing – Grand Ballroom – 1st Floor Cancer Patient Portal demonstration (lunchtime, Monday, 8th June) – Dublin 1&2 – 2nd Floor Dragons Den (lunchtime, Tuesday, 9th June) – Library Bar – access by stairs beside registration desk (Ground Floor). Please note that lunch will be served in the Library Bar for those who are attending this session. AGM of UK & Ireland Association of Cancer Registries (Morning, Wednesday, 10th June) – Library Bar – access by stairs beside registration desk (Ground Floor). 20 Visit our stand! PHE has a critical role in the national response to cancer. Find out what we are doing to prevent cancer and improve outcomes for patients across the cancer pathway, including: • • • • • • • • • • national programmes on behavioural risk factors health marketing data and intelligence screening and immunisation protection from infection-related cancers preventing infection related morbidity and mortality in cancer activity to address radiation, chemical and environmental hazards reducing inequalities supporting the commissioning of cancer services supporting innovation and improvement in end of life care PHE teams working on cancer include: • • • • • • • • • National Cancer Intelligence Network National Cancer Registration Service National End of Life Care Intelligence Network Be Clear on Cancer marketing campaigns Screening Immunisation, hepatitis and blood safety Healthy people Alcohol, drugs and tobacco Centre for radiation, chemical and environmental hazards www.gov.uk/phe 21 Poster Information Poster setup All posters will be displayed in the Grand Ballroom. On arrival, all poster presenters should register and then put their poster up as soon as possible on the day of their presentation. Poster numbers are given in this brochure. Display boards are numbered in the Grand Ballroom, Velcro is provided. Poster viewings All poster presenters are encouraged to stand by their poster during the breaks. Poster prizes The National Cancer Intelligence Network (NCIN) is delighted to announce that there will be several poster awards presented at the Cancer Outcomes Conference 2015. Award winners will be announced on Wednesday 10 June by Chris Carrigan, Head of the National Cancer Intelligence Network. 1st, 2nd and 3rd places will be awarded and 1st place will receive a prize – authors should be available to collect prize at the close of the conference. The prize categories are: a. Cancer Screening, Early Diagnosis of Cancer b. Changing Clinical Practice/Supporting Commissioning/Audit c. Childhood, Teenage & Young Adults d. Epidemiology, Inequalities and Less Common Cancers e. Patient Reported Outcome/Experience Measures f. Survivorship/Late Effects of Cancer and Treatment g. All other categories combined h. Patient Choice Poster Prize Awards x 2 The National Cancer Intelligence Network would like to thank the judging panel for their contribution. Poster removal Day 1 posters should be removed on Monday from 17:20 and Day 2 posters on Tuesday from 17:25. Posters that have been shortlisted for a prize will be displayed on Day 3. If your poster has been shortlisted for a prize there will be a sticker on your poster stating ‘Congratulations your poster has been shortlisted for the poster prize awards on Wednesday 10 June. Please do not remove your poster. The conference organisers will remove your poster today and re-erect it for display on Wednesday morning alongside the other finalists. Please note that posters left after the times above will be recycled. 22 Speaker Information To check your presentation Please visit the slide preview room (Copenhagen 2, 2nd floor) to allow a quick final check through your presentation. The slide preview room will be open during the following times: Monday 8 June 08:00-11:00 13:20-13:50 15:20-15:50 Tuesday 9 June 08:00-09:00 10:30-11:00 13:00-14:00 15:30-16:00 Wednesday 10 June 08:30- 09:30 To facilitate sharing of knowledge and expertise, a PDF of your presentation will go on the conference website after the conference. In the session Please check the time and venue of your session in the conference programme. Kindly arrive in good time before your session is due to start to meet the session chair and technician. The technician and a member of the conference staff will be in the room throughout the session to make sure it runs smoothly. The chair has been provided with your biography and abstract to facilitate your introduction. Please observe the time given for your presentation in email correspondence. You will not be permitted to speak for longer than this. Microphones will be available for Q&As. Plenary sessions will have Q&A at the end of each session whereas parallel sessions will have Q&A after each presentation. 23 Did you know… …that we have famous inventors • Belfast’s Sirocco Works invented air conditioning and the Royal Victoria Hospital Belfast became the first building in the world to be fitted with air conditioning. • Mary McAleese, President of Ireland is not the only state president to have been born in Belfast. Chaim Herzog, Israel’s first president was the son of a Belfast rabbi. • Milk of Magnesia was invented by Sir James Murray in Belfast in 1829. • The tractor was invented by Harry Ferguson, the first man in Ireland to build and fly his own aeroplane. • London’s Sloane Square and Sloanies are named after County Down born and Belfast educated Sir Hans Sloane, the man responsible for first creating milk chocolate. By the nineteenth century, the Cadbury Brothers sold tins of Sloane's drinking chocolate. 24 2015 1–4 November 2015 BT Convention Centre Liverpool, UK Join us at the 2015 NCRI Cancer Conference The largest cancer research meeting in the UK Register by 31 July for earlybird rates Be part of the largest cancer research meeting in the UK Discover, share and collaborate with colleagues from across the globe Be inspired by over 120 speakers across 50 sessions Late breaking abstract submission opens 3 August 2015 Showcase your research and receive feedback from your peers Ensure your work is accessible to the UK and international research community Gain recognition from your peers with dedicated viewing times New for 2015: Poster discussion session Attend the poster discussion session to view top quality abstract presentations Programme: Monday 8 June DAY ONE – MONDAY 8 JUNE (6 CPD Credits) 09:30 – 11:00 Conference Registration Grand Ballroom Erection of Day 1 Posters, Exhibition & Poster Viewing Refreshments 11:00 – 12:30 Exhibition Centre Welcome & Plenary Session 1: Changing clinical practice: Importance of routine data and cancer registries Chair: Mr Chris Carrigan, Head of the National Cancer Intelligence Network 11:00 – 11:10 Welcome Dr Michael McBride, Chief Medical Officer, Department of Health, Social Services and Public Safety Northern Ireland 11:10 – 11:20 What patients want from their data Mrs Margaret Grayson, Chair of the Northern Ireland Cancer Research Consumer Forum, and PPI representative on the NI Cancer Trials Centre (NICTC) Executive 11:20 – 11:30 The importance of data to the voluntary sector, for policy development and improving patient care Miss Sara Hiom, Director, Early Diagnosis and Cancer Intelligence Policy & Information, Cancer Research UK 11:30 – 11:50 Use of routine data in the monitoring and evaluation of bowel screening Professor Robert JC Steele, Professor of Surgery and Head of Cancer Research, University of Dundee 11:50 – 12:05 Improving cancer Outcomes – the role of audit, clinical and provider level data in improving lung cancer survival Dr Mick Peake, National Clinical Lead, National Cancer Intelligence Network, Public Health England 12:05 – 12:20 The impact of linked data – examples of benefits in practice Dr Jem Rashbass, National Director for disease registration at Public Health England 12:20 – 12:30 Questions to the Speakers & Chair’s Closing Remarks Mr Chris Carrigan, Head of the National Cancer Intelligence Network 26 Programme: Monday 8 June 12:30 – 13:50 Grand Ballroom Lunch Exhibition & Poster Viewing 13:15 – 13:30 Dublin 1&2 Cancer Patient Portal demonstration 13:50 – 15:20 Parallel Sessions Session 1 Exhibition Centre Early Diagnosis of Cancer Chair: Dr Yoryos Lyratzopoulos, Reader in Cancer Epidemiology, UCL; Cancer Research UK Clinician Scientist Fellow 13:50 – 14:05 Recent research into symptomatic cancer diagnosis: the UK and international landscape Dr Christine Campbell, Centre for Population Health Sciences, University of Edinburgh 14:05 – 14:20 Features of the diagnostic pathway associated with early death from colon cancer: A nested case control study in a UK region Mr Conan Donnelly, N. Ireland Cancer Registry, Queen’s University Belfast 14:20 – 14:35 An examination of referral patterns following Be Clear on Cancer campaigns Mr John Broggio, Public Health England Knowledge & Intelligence Team West Midlands 14:35 – 14:50 Association between use of the English urgent referral pathway for suspected cancer and mortality outcome in cancer patients: cohort study Professor Henrik Møller, Professor of Cancer Epidemiology at King’s College London, School of Medicine & Director of Cancer Epidemiology and Population Health in King’s Health Partners Cancer Centre 14:50 – 15:05 Patients and Primary Care benefit from Direct Access Endoscopy Services Miss Helen Pardoe, Homerton University NHS Trust 15:05 – 15:20 Discussion and Chair’s Closing Remarks Dr Yoryos Lyratzopoulos, Reader in Cancer Epidemiology, UCL; Cancer Research UK Clinician Scientist Fellow 27 Programme: Monday 8 June Session 2 Penthouse Suite Data Processing, Management & National Systemic Anti-Cancer Therapy (SACT) data Chair: Dr Jem Rashbass, National Director for disease registration, Public Health England 13:50 – 14:05 Estimating ascertainment for reported activity within the SACT dataset Mr Michael Wallington, Public Health England 14:05 – 14:20 Reviewing early mortality following cytotoxic chemotherapy: a NCIN analysis of SACT data Professor David Dodwell, Institute of Oncology, St James Hospital, Leeds 14:20 – 14:35 Using natural language processing to automatically extract cancer outcomes data from clinical notes Mr Tom Liptrot, The Christie NHS Foundation Trust, Manchester 14:35 – 14:50 Comparing the multiple sources of cancer treatment data Mr Sean McPhail, National Cancer Intelligence Network (NCIN), Public Health England 14:50 – 15:05 Cascade and Cancerstats: A Shared Platform for NCRS Reporting Mrs Sally Vernon, National Cancer Registration Service, Public Health England 15:05 – 15:20 Discussion and Chair’s Closing Remarks Dr Jem Rashbass, National Director for disease registration, Public Health England 28 Programme: Monday 8 June Session 3 Dublin 1&2 Treatments Chairs: Dr Martin Eatock, Oncologist, Medical Advisor of N. Ireland Cancer Network and Dr John Graham, Director of National Collaborating Centre for Cancer, Wales 13:50 – 14:00 The use of population and research data in the development of guidelines for cancer treatment Dr John Graham, Director of National Collaborating Centre for Cancer, Wales 14:00 – 14:15 The order of radiotherapy and chemotherapy in early breast cancer and its effect on outcome Professor Sabine Siesling, Netherlands Comprehensive Cancer Organisation (IKNL) 14:15 – 14:30 Robotic surgery in gynaecological oncology Dr Thumuluru Kavitha Madhuri, Royal Surrey County Hospital NHS Foundation Trust 14:30 – 14:45 Variation in the proportion of patients with lymphoma receiving radiotherapy (England 2009-2010) Mrs Sarah Lawton, Northern & Yorkshire Knowledge and Intelligence Team, Public Health England 14:45 – 15:00 Treatment of stage I cervical cancer in England: results from the national audit of cervical screening Professor Peter Sasieni, Centre For Cancer Prevention, Wolfson Institute of Preventive Medicine, London 15:00 – 15:15 Regional variation in length of hospital stay after major surgery for colorectal cancer Dr Kate Walker, London School of Hygiene and Tropical Medicine 15:15 – 15:20 Discussion and Chair’s Closing Remarks Dr Martin Eatock, Oncologist, Medical Advisor of N. Ireland Cancer Network Dr John Graham, Director of National Collaborating Centre for Cancer, Wales 15:20 – 15:50 Refreshments Grand Ballroom Exhibition & Poster Viewing 29 Programme: Monday 8 June 15:50 – 17:20 Exhibition Centre Plenary Session 2: Role of Primary Care in Cancer Prevention, Screening and Early Diagnosis Chairs: Professor Greg Rubin, Professor of General Practice and Primary Care, Durham University and Roger Wilson CBE, Hon President Sarcoma UK, past Chair NCRI Consumer Liaison Group, patient member NCIN SSCRG for Sarcoma 15:50 – 16:05 Chair’s Introduction Professor Greg Rubin, Professor of General Practice and Primary Care, Durham University 16:05 – 16:25 International Cancer Benchmarking Partnership: Module 4 Results Professor David Weller, Head of the General Practice Section in the Division of Community Health Sciences, University of Edinburgh 16:25 – 16:45 To what extent do provider delays affect outcomes? Dr Peter Murchie, Senior Clinical Lecturer in Academic Primary Care, University of Aberdeen 16:45 – 17:05 How can primary care data help set referral thresholds? Professor Willie Hamilton, Professor of Primary Care Diagnostics, University of Exeter 17:05 – 17:20 Questions to the Speakers & Chair’s Closing Remarks Mr Roger Wilson CBE, Hon President Sarcoma UK, past Chair NCRI Consumer Liaison Group, patient member NCIN SSCRG for Sarcoma 17:20 Close of Day 1 Grand Ballroom Removal of Day 1 posters 18:45 Networking Event: Welcome Reception with Buffet Dinner, Belfast City Hall (tickets required) 30 Plenary Session 1 Changing clinical practice: Importance of routine data and cancer registries What patients want from their data Mrs Margaret Grayson Chair of the Northern Ireland Cancer Research Consumer Forum, and PPI representative on the NI Cancer Trials Centre (NICTC) Executive Data! This is a small word with big importance. The Conference theme is “United against Cancer” - central to all that is presented over these next three days is data and how it is used. Patients are an essential part of this partnership with researchers. So what is needed from our data to ensure the right research questions are asked – research that benefits and impacts on prevention, diagnosis, treatment, services, care and survivorship. What are our rights and responsibilities? Would we set boundaries on access? Listen to the patient voice! The importance of data to the voluntary sector, for policy development and improving patient care Miss Sara Hiom Director, Early Diagnosis and Cancer Intelligence Policy & Information, Cancer Research UK Technology and enhanced data extraction have been catalysts for a massive proliferation of datasets placing more information at our fingertips than ever before. The opportunities these data offer are clear, but the value is not inherent; it is found in the subsequent generation of intelligence and translational application to policy and practice. Within this we need to distinguish when information can offer the answer to a question and when it is providing the insight which allows us to ask the right ones. The challenge for our organisations is to ensure that this sheer volume of data doesn’t ‘drown out’ accurate analysis, but rather informs the best decisions to improve care along the patient pathway. Use of routine data in the monitoring and evaluation of bowel screening Professor Robert JC Steele Professor of Surgery and Head of Cancer Research, University of Dundee In Scotland, using data from the colorectal cancer screening database, the Scottish Cancer Registry and the National Records of Scotland, it was possible to demonstrate a 10% reduction in disease specific mortality in the population that was offered screening between 2000 and 2006, (27% when corrected for participation). However, in addition to verifying the effect on mortality routinely collected data is used to populate key performance indicators addressing uptake, positivity, waiting times, colonoscopy quality, stage of diagnosis, polyp detection rates and positive predictive value. These data are scrutinised by the Monitoring and Evaluation Group for The Scottish Bowel Screening Programme. 31 Plenary Session 1 Improving cancer Outcomes – the role of audit, clinical and provider level data in improving lung cancer survival Dr Mick Peake National Clinical Lead, National Cancer Intelligence Network, Public Health England In a number of studies lung cancer survival in the UK has been demonstrated to be worse than in many other parts of the Western world. The National Lung Cancer Audit (NLCA) has been collecting population-based data since 2005, the quality and completeness of which is now excellent. There has been strong clinical engagement with the programme and the findings have been regularly fed-back to provider clinical teams in a variety of ways. There have been year-on-year improvements in all of the headline indicators, in particular the proportion of patients undergoing surgical resection. In fact the number of patients in the UK having surgical treatment for their lung cancer has virtually doubled between 2005 and 2012. Wide variations between providers in treatment rates and survival remain, but the range of that variation has also lessened over time. We have demonstrated a fall in mortality in the lung cancer population since 2008, particularly in patients with early stage disease. Two separate survival analyses have demonstrated a significant improvement in the proportion of patients alive one year after diagnosis between 2004/7 and 2012, bringing the UK rates nearer to those seen in other countries. High quality data combined with clinical engagement can clearly result in better outcomes for patients and should be the driving force behind cancer intelligence initiatives. The impact of linked data – examples of benefits in Practice Dr Jem Rashbass National Director for disease registration at Public Health England Over the last few years we have made considerable progress collecting data through the National Cancer Registration Service in England. We will soon be able to provide near-realtime analysis of much of the patient journey, the quality of care and outcomes of all cancer patients treated in England. Patients, their carers and the professional that look after them are key players and in this presentation I will outline some of our achievements and our plans for the coming year. 32 Plenary Session 2 Role of Primary Care in Cancer Prevention, Screening and Early Diagnosis International Cancer Benchmarking Partnership: Module 4 Results Professor David Weller Head of the General Practice Section in the Division of Community Health Sciences, University of Edinburgh The ICBP has compared cancer survival in participating countries around the world. Module 4 examines routes to diagnosis; the ways cancer are diagnosed (through screening, via emergency presentation, via primary care etc.) and in key diagnostic intervals – patient intervals, time from first presentation to primary care and referral to cancer services and time taken in the diagnostic and treatment process. Patients are recruited via cancer registries, with target numbers of 200 for breast, colorectal, lung and ovarian cancer. Patient responses have been supplemented with surveys of primary care providers, treating specialists and existing data. Whilst analyses are still underway, early indications are that important differences will be found; implications for cancer strategy will be discussed. To what extent do provider delays affect outcomes? Dr Peter Murchie Senior Clinical Lecturer in Academic Primary Care, University of Aberdeen In cancer diagnosis, provider delay represents the period of time between a patient presenting with symptoms to their GP and the time by which they receive definitive treatment. Long provider delays are worrisome for patients and their families and frustrating for doctors. Whether longer provider delays actually worsen outcomes, in terms of stage at diagnosis and survival from cancer is less well known. In this talk current evidence on the link between the length of provider delay and outcomes in colorectal cancer, from a number of international studies, will be reviewed. How can primary care data help set referral thresholds? Professor Willie Hamilton Professor of Primary Care Diagnostics, University of Exeter Any clinical guidance on selecting a group for cancer investigation means that others are not selected. This binary split brings the concept of a threshold for selection. In this contribution, four main areas will be covered: The overall concept of a threshold value, and which metric(s) should be used for it? Which factors should be used to establish the level of the threshold – and whose perspectives should inform this? Should there be a single threshold value, or are particular groups meriting a different threshold? Is the concept practical – do we have sufficient data to use any selected threshold, anyway? 33 Did you know… …that the city hall in Durban, South Africa is almost an exact replica of Belfast's City Hall? …that Professor Sir Frank Pantridge (1916–2004) was a physician and cardiologist born in Hillsborough,12 miles from Belfast who invented the portable defibrillator? …that Lord Kelvin born on 26 June 1824 in Belfast created the first physics laboratory in Britain? He was a pioneer in many different fields, particularly electromagnetism and thermodynamics and Kelvin temperature scale. …that C.S. Lewis born on November 29, 1898, in Belfast, was a prolific Irish writer and scholar best known for his Chronicles of Narnia fantasy series as well as his pro-Christian texts? C.S. Lewis went on to teach at Oxford University and became a renowned apologist writer, using logic and philosophy to support the tenets of his Christian faith. 34 Programme: Programme: Tuesday Tuesday 99 June June DAY TWO – TUESDAY 9 JUNE (6 CPD Credits) 08:00 – 08:45 Conference Registration Grand Ballroom Erection of Day 2 Posters, Exhibition & Poster Viewing 08:45 – 10:30 Exhibition Centre Plenary Session 3: International issues in cancer Chairs: Mr Richard Stephens, Chair of NCRI’s Consumer Forum and co-chair of the Advisory Group for NIHR’s Dissemination Centre and Professor Patrick Johnston, Vice-Chancellor, Queen’s University Belfast 08:45 – 08:55 Chair’s Introduction Professor Patrick Johnston, Vice-Chancellor, Queen’s University Belfast 08:55 – 09:15 International hazards of smoking and benefits of stopping Professor Sir Richard Peto, Professor of Medical Statistics & Epidemiology and Co-Director of the Clinical Trial Service Unit, University of Oxford 09:15 – 09:35 International cancer burden and trends – the role of diet and exercise Dr Isabelle Soerjomataram, Section of Cancer Surveillance, International Agency for Research on Cancer 09:35 – 09:55 International Cancer Benchmarking Partnership – studying international variations in cancer survival Miss Sara Hiom, Director, Early Diagnosis and Cancer Intelligence Policy & Information, Cancer Research UK 09:55 – 10:15 Global surveillance of cancer survival (CONCORD) Professor Michel Coleman, Professor of Epidemiology and Vital Statistics, London School of Hygiene & Tropical Medicine 10:15 – 10:30 Questions to the Speakers & Chair’s Closing Remarks Mr Richard Stephens, Chair of NCRI’s Consumer Forum and co-chair of the Advisory Group for NIHR’s Dissemination Centre 10:30 – 11:00 Refreshments Grand Ballroom Exhibition & Poster Viewing 35 Programme: Programme: Tuesday Tuesday 99 June June 11:00 – 12:30 Parallel Sessions Session 4 Exhibition Centre Changing Clinical Practice Chairs: Dr Robin Ireland, Consultant Haematologist, King’s College Hospital, & Chair of Haematology SSCRG, National Cancer Intelligence Network, Public Health England and Dr Fran Woodard, Director for England, Policy and Research, Macmillan Cancer Support 11:00 – 11:15 Decreasing time from head and neck cancer surgery to post-operative radiotherapy in a regional cancer centre Mr Mohamed Abdulla, South West Wales Cancer Centre, Singleton Hospital 11:15 – 11:30 Cancer Waiting times - New Zealand Style Ms Di Riley, Southern Cancer Network, New Zealand 11:30 – 11:45 Using the National Radiotherapy Dataset within the National Cancer Data Repository to investigate patterns of use of radiotherapy in the management of surgically treated rectal cancer across the English NHS Dr Eva Morris, University of Leeds. 11:45 – 12:00 Ensuring rapid response for intravenous antibiotics for neutropenic patients experiencing suspected sepsis: Nurse initiated Patient Group Direction (PGD) improves patient outcome and experience Mr Gavin Cooper, UCLH NHS Foundation Trust, London 12:00 – 12:15 Transitioning through phases of care: Building understanding of diversity in the cancer population through classification Professor Jane Maher, Mount Vernon Cancer Centre and Macmillan Cancer Support 12:15 – 12:30 Discussion and Chair’s Closing Remarks Dr Robin Ireland, Consultant Haematologist, King’s College Hospital, & Chair of Haematology SSCRG, National Cancer Intelligence Network, Public Health England and Dr Fran Woodard, Director for England, Policy and Research, Macmillan Cancer Support 36 Programme: Programme: Tuesday Tuesday 99 June June Session 5 Penthouse Suite Prevention Chair: Professor John Newton, Chief Knowledge Officer, Public Health England 11:00 – 11:15 Oral statin use associated with reduced risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based nested casecontrol study Dr Charlene M. McShane, Centre for Public Health, Queen's University Belfast 11:15 – 11:30 Monitoring HPV immunisation and the changing epidemiology of HPV to inform integrated cervical cancer prevention strategies Mr David Mesher, Public Health England 11:30 – 11:45 Modifiable risk factors for colorectal serrated polyps: a systematic review and meta-analysis Dr Helen Coleman & Ms Lesley Bailie, Centre for Public Health, Queen's University Belfast 11:45 – 12:00 Dietary magnesium, calcium:magnesium ratio and risk of reflux esophagitis, Barrett’s esophagus and esophageal adenocarcinoma Professor Qi Dai, Vanderbilt Epidemiology Center, Vanderbilt University 12:00 – 12:15 Increasing uptake in the bowel cancer screening programme with GP participation: the PEARL Project Mrs Sally Benton, NHS Bowel Cancer Screening Programme - Southern Hub 12:15 – 12:30 Discussion and Chair’s Closing Remarks Professor John Newton, Chief Knowledge Officer, Public Health England 37 Programme: Tuesday 9 June Session 6 Dublin 1&2 Childhood, Teenage & Young Adults Chair: Dr Martin McCabe, Chair Childhood Site Specific Clinical Reference Group of NCIN 11:00 – 11:10 Patient story Mr Niall Connor, Cancer Fund for Children Service User 11:10 – 11:25 Population-based long-term respiratory mortality among 267,570 5-year survivors of cancer diagnosed before age 40 years Miss Miranda Fidler, Centre for Childhood Cancer Survivor Studies, University of Birmingham 11:25 – 11:40 Time trends and Factors associated with Childhood Cancer Survival in Switzerland: a Population Based Cohort Study Mr Matthias Schindler, Institute of Social and Preventive Medicine, University of Bern 11:40 – 11:55 Mode of diagnosis and outcomes for children diagnosed with renal tumours in the UK and in Germany Professor Kathy Pritchard-Jones, Institute of Child Health, University College London 11:55 – 12:10 Cerebrovascular complications in 208,769 5-year survivors of cancer diagnosed aged 15-39 years using hospital episode statistics: the population-based teenage and young adult cancer survivor study (TYACSS) Miss Chloe Bright, Centre for Childhood Cancer Survivor Studies, University of Birmingham 12:10 – 12:25 Patterns of hospital admissions and length of stay during 1996 to 2011 among children compared with teenagers and young adults after completing treatment following diagnosis with cancer in Yorkshire Mrs Arwa Althumairi, Division of Epidemiology & Biostatistics School of Medicine University of Leeds 12:25 – 12:30 Discussion and Chair’s Closing Remarks Dr Martin McCabe, Chair Childhood Site Specific Clinical Reference Group of NCIN 38 Programme: Tuesday 9 June 12:30 – 14:00 Lunch Grand Ballroom Exhibition & Poster Viewing Library Bar CRUK Dragon’s Den (pre-booking required) 14:00 – 15:30 Parallel Sessions Session 7 Dublin 1&2 Site Specific Clinical Reference Group– Urology Cancers Chairs: Mr Roger Kockelbergh, Urology SSCRG Chair, University Hospitals Leicester NHS Trust, Leicester and Professor Joe O’Sullivan, Professor of Radiation Oncology, Queen’s University Belfast & Oncology Lead Belfast Health & Social Care Trust 14:00 – 14:15 Variation in usage of radical prostatectomy and radical radiotherapy for men with locally advanced prostate cancer Dr Luke Hounsome, Public Health England, Knowledge and Intelligence Team (South West) 14:15 – 14:30 Measurement of bladder cancer recurrence on a national scale: A pilot study Mr Roger Kockelbergh, University Hospitals Leicester NHS Trust, Leicester 14:30 – 14:45 Cardiovascular Outcomes in Kidney Cancer Patients Ms Elsie Mensah, Imperial College London 14:45 – 15:00 Non-TCC Histology Only Partly Explains Adverse Survival Outcomes in Females with Bladder Cancer - A Summary of UK Epidemiological Data Dr Kathryn Ball, University Hospitals Leicester NHS Trust 15:00 – 15:15 Prostate Cancer: Prostate cancer patient reported outcomes - Does more investigation and treatment result in better health? Dr Anna Gavin, N. Ireland Cancer Registry, Queen’s University Belfast 15:15 – 15:30 Discussion and Chair’s Closing Remarks Mr Roger Kockelbergh, Urology SSCRG Chair, University Hospitals Leicester NHS Trust, Leicester Professor Joe O’Sullivan, Professor of Radiation Oncology, Queen’s University Belfast & Oncology Lead Belfast Health & Social Care Trust 39 Programme: Tuesday 9 June Session 8 Exhibition Centre Survivorship Chair: Professor Jane Maher, Chief Medical Officer, NHS Clinical Leader and Consultant Clinical Oncologist, Macmillan Cancer Support 14:00 – 14:15 Does the risk of critical illness among cancer patients make a significant contribution to cancer outcomes? - a population-based observational study of 118,571 adults from the Scottish Cancer Registry Dr David Morrison, The West of Scotland Cancer Surveillance Unit, University of Glasgow 14:15 – 14:30 Transforming Cancer Follow-up Programme Mrs Edel Aughey, Northern Ireland Cancer Network (NICaN) 14:30 – 14:45 Characteristics of long-term survivors of Head and Neck cancer within UK Biobank Dr Tatiana Macfarlane, University of Aberdeen School of Medicine and Dentistry 14:45 – 15:00 Testing and analysis of a risk stratified Computed Tomography scanning protocol for the follow-up of patients post curative resection of colorectal adenocarcinoma Mr Henry Watson, Bradford Royal Infirmary 15:00 – 15:15 Keeping The Customers Satisfied? Findings from NCPES About Patients and Research Opportunities Mr Richard Stephens, NCRI Consumer Forum 15:15 – 15:30 Discussion and Chair’s Closing Remarks Professor Jane Maher, Chief Medical Officer, NHS Clinical Leader and Consultant Clinical Oncologist, Macmillan Cancer Support 40 Programme: Tuesday 9 June Session 9 Penthouse Suite Epidemiology/Clinical trials Chair: Professor Henrik Møller, Professor of Cancer Epidemiology at King’s College London, School of Medicine & Director of Cancer Epidemiology and Population Health in King’s Health Partners Cancer Centre 14:00 – 14:15 Risk of Oesophageal Cancer among Patients Previously Hospitalised with Eating Disorder Dr David Brewster, NHS National Services Scotland 14:15 – 14:30 Seasonal variation in diagnosis of invasive cutaneous melanoma in Eastern England and Scotland Dr Fiona Walter, University of Cambridge 14:30 – 14:45 Comorbidities, late diagnosis, an International comparison of Small cell lung cancer Mr Patrick Suddaby, West of Scotland Cancer Surveillance Unit, Glasgow 14:45 – 15:00 The need for standardised outcomes in cancer clinical trials: a report of cancer core outcome sets Miss Elizabeth Gargon, University of Liverpool 15:00 – 15:15 Impact of post-operative wound complications on longterm survival from breast cancer: population-based retrospective cohort study in Scotland Miss Catherine S Thomson, NHS National Services Scotland 15:15 – 15:30 Discussion and Chair’s Closing Remarks Professor Henrik Møller, Professor of Cancer Epidemiology at King’s College London, School of Medicine & Director of Cancer Epidemiology and Population Health in King’s Health Partners Cancer Centre 15:30 – 16:00 Refreshments Grand Ballroom Exhibition & Poster Viewing 41 Programme: Tuesday 9 June 16:00 – 17:30 Exhibition Centre Plenary Session 4: Childhood, Teenage and Young Adult Cancers, Beyond Cancer Survival Chair: Dr Martin McCabe, Chair Childhood Site Specific Clinical Reference Group of NCIN 16:00 – 16:10 Patient’s Story Dr Tom Grew 16:10 – 16:30 EUROCARE survival data: where the UK sits internationally Dr Gemma Gatta, Research Assistant at the Epidemiology Unit, Istituto Nazionale dei Tumori, Milan 16:30 – 16:50 The follow-up of 250,000 individuals treated for cancer when young Professor Mike Hawkins, Professor of Epidemiology Public Health, Epidemiology and Biostatistics, University of Birmingham 16:50 – 17:10 SIGN Guidance Professor Hamish Wallace, Consultant Paediatric Oncologist, RHSC, Edinburgh and Honorary Professor in the School of Clinical Sciences and Community Health, University of Edinburgh 17:10 – 17:25 Questions to the Speakers and Chair’s Closing Remarks Dr Martin McCabe, Chair Childhood Site Specific Clinical Reference Group of NCIN 17:25 Close of Day 2 Grand Ballroom Removal of Day 2 posters and erection of posters shortlisted for poster prizes 18:30 Buses Depart Europa (side entrance Glengall Street) for Titanic Belfast (pre-booking required) 19:00 Dinner Titanic Belfast (tickets required) 42 Plenary Session 3 International Issues in Cancer International hazards of smoking and benefits of stopping Professor Sir Richard Peto Professor of Medical Statistics & Epidemiology and Co-Director of the Clinical Trial Service Unit, University of Oxford Recent studies of the hazards of people in the United Kingdom, USA, or Japan who began smoking in adolescence or early adult life show loss of about 10 years of life expectancy if they continue, and avoidance of more than 90% of the excess risk if they stop before age 40 (and preferably well before age 40). Smokers who did not start in early adult life have much smaller hazards in middle and old age. Hence, when smoking becomes common among a population of young adults, the full eventual effects of tobacco on mortality rates in middle and old age take more than half a century to emerge in that population. For women in many developed countries and men in many other countries, there will be a large increase in tobacco-attributed mortality over the next few decades as a result of increases in smoking that have already happened, unless there is widespread cessation (Peto et al, IARC/WHO 2014 World Cancer Report). International cancer burden and trends – the role of diet and exercise Dr Isabelle Soerjomataram Section of Cancer Surveillance, International Agency for Research on Cancer Excess body mass index is a known risk factor for several major cancers including oesophageal adenocarcinoma, colon, rectal, kidney, pancreas, gallbladder, post-menopausal breast, ovarian and endometrial cancer. In the United Kingdom we have witnessed an overwhelming rise of BMI: in 1980 around 38% of adults were overweight compared to 62% in 2013, rising concerns on the impact on cancer. In this project, we estimated the cancer incidence related to high BMI in the UK and other countries worldwide, taking into account the use of hormone replacement therapy (HRT) and tobacco smoking. Additionally studies the cumulative impact of overweight of the life course will be shown. Reflecting on the current trend of excess BMI, we are facing a new challenge in cancer control and understanding the impact of high BMI will become increasingly important. International Cancer Benchmarking Partnership – studying international variations in cancer survival Miss Sara Hiom Director, Early Diagnosis and Cancer Intelligence Policy & Information, Cancer Research UK The International Cancer Benchmarking Partnership (ICBP) is a unique global partnership of clinicians, academics and policymakers across 6 countries (UK, Australia, Canada, Denmark, Norway and Sweden) with high-quality and long standing cancer registration, similar health systems and comparable health care spending. The partnership seeks to understand how cancer survival varies between countries, and is generating insights into what is contributing to these differences. These insights are helping partners to identify how they might improve cancer survival outcomes by optimising cancer policies and services. This session will highlight the unique perspective of the partnership and its findings and impacts to date. 43 Plenary Session 3 Global surveillance of cancer survival (CONCORD) Professor Michel Coleman Professor of Epidemiology and Vital Statistics, London School of Hygiene & Tropical Medicine We analysed data for 25·7 million adults and 75 000 children diagnosed with one of 10 common cancers during 1995–2009, submitted by 279 population-based cancer registries in 67 countries. We estimated age-standardised 5-year net survival, corrected for background mortality by age, sex, calendar year, geography and race/ethnicity. The widely disparate survival trends are probably attributable to differences in access to early diagnosis and optimal treatment: thus, survival from childhood acute lymphoblastic leukaemia, nowadays considered largely curable, ranges from below 60% in some countries to 90% or above in others. Continuous worldwide surveillance of cancer survival will become a comparative metric stimulating improvement in the effectiveness of healthcare systems. 44 Plenary Session 4 Childhood, Teenage and Young Adult Cancers, Beyond Cancer Survival Patient’s Story Dr Tom Grew “A personal story of surviving cancer – good and bad. This will include my journey from diagnosis, through treatment and then into survivorship. I will discuss the information given to me along the way in terms of late effects, as well as what I wish I had been told. I will particularly focus on what it was like to have cancer and then have late effects as a young person. This will include the positive as well as the negative impact this has had on my life.” EUROCARE survival data: where the UK sits internationally Dr Gemma Gatta Research Assistant at the Epidemiology Unit, Istituto Nazionale dei Tumori, Milan Survival and cure rates for childhood cancers in Europe have greatly improved over the past 40 years and are mostly good, although not in all European countries. Over the past 20 years, EUROCARE produced population-based cancer survival that depicts the situation in Europe as accurately as possible. With EUROCARE-5 we analyzed about 60,000 children with cancer from 28 countries, accounting for 77% of the childhood population of Europe. 5-year survival for all childhood cancers combined improved from 76%, in the late 1990s to 79%in the early 2000s. However, survival disparities between countries and European regions persisted. The follow-up of 250,000 individuals treated for cancer when young Professor Mike Hawkins Professor of Epidemiology Public Health, Epidemiology and Biostatistics, University of Birmingham The original British Childhood Cancer Survivor Study (BCCSS) related to 18000 individuals diagnosed with cancer before 1992 and who survived at least 5 years. Studies of risks of specific causes of death beyond 5-year survival, and the risks and causes of subsequent primary neoplasms have been undertaken. A postal questionnaire concerned with health and social outcomes was sent to 15000 survivors and 10500 returned it completed. The BCCSS was recently extended to include 17000 5-year survivors of cancer diagnosed between 1992 and 2006 and now relates to 35000 5-year survivors – www.bccss.bham.ac.uk. The Teenage and Young Adult Cancer Survivor Study (TYACCS) relates to 230000 individuals diagnosed with cancer between 1971 and 2006 when aged 15 to 39 years. The BCCSS and TYACCS cohorts have recently been linked to the national Hospital Episode Statistics database for England and linkage with the databases held by the National Institute for Cardiovascular Outcomes Research (NICOR) is underway. Pan-European case-control studies of specific subsequent primary neoplasms, cardiac disease and strokes are underway with FP-7 grants from the EC: PanCareSurFup, PROCARDIO and CEREBRAD. 45 Plenary Session 4 SIGN Guidance Professor Hamish Wallace Consultant Paediatric Oncologist, RHSC, Edinburgh and Honorary Professor in the School of Clinical Sciences and Community Health, University of Edinburgh For all childhood cancers the five-year survival rate has improved over recent decades from 30% in the 1960’s to 80% for children diagnosed between 2001 and 2005, due to advances in treatment regimens and better supportive care. Late effects of treatment may occur soon after completion or many years later; it is possible that survivors may benefit from targeted screening, detection and treatment SIGN recommendations are based on systematic reviews of best available evidence. The composition of the guideline development group will be discussed and the journey from formation of the group to the production of the guideline will be presented. To improve care of survivors of childhood cancer, the guideline recommends that each survivor has access to an appropriate designated key worker who will coordinate care, and that a training programme and career structure should be developed for nurse practitioners specialising in long term follow-up. A short summary of the full guideline SIGN 132 is available on the SIGN guideline app, and on the web at: http://www.sign.ac.uk/pdf/sign132.pdf 46 Programme: Wednesday 10 June DAY THREE – W EDNESDAY 10 JUNE (3 CPD Credits) 08:30 – 09:30 Conference Registration Library Bar AGM of UK & Ireland Association of Cancer Registries Grand Ballroom Exhibition & Viewing Poster Finalists 09:30 – 11:00 Parallel Sessions Session 10 Dublin 1&2 Pharmaco-Epidemiology Chair: Professor Liam Murray, Acting Director, Centre for Public Health, Queen’s University Belfast 09:30 – 09:45 Associations between pre- and post-diagnostic use of beta-blockers and ovarian cancer survival Mr Chris Brown, National Cancer Registry Ireland 09:45 – 10:00 Metformin use and survival after colorectal cancer: A population-based cohort study Dr Úna Mc Menamin, Centre for Public Health, Queen’s University Belfast 10:00 – 10:15 Statin use after colorectal cancer diagnosis and survival: a population-based cohort study Miss Blànaid Hicks, Centre for Public Health, Queen’s University Belfast 10:15 – 10:30 Is there nationwide variation in the proportion of oesophago-gastric cancers diagnosed at an early stage? Dr David Cromwell, Royal College Of Surgeons Of England 10:30 – 10:45 Trends in adenocarcinoma and squamous cell carcinoma of the oesophagus in England: 1970s to 2012 Dr Judith Offman, Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, QMUL 10:45 – 11:00 Discussion and Chair’s Closing Remarks Professor Liam Murray, Acting Director, Centre for Public Health, Queen’s University Belfast 48 Programme: Wednesday 10 June Session 11 Penthouse Suite Health Economics Chair: Professor Brian Ferguson, Chief Economist, Public Health England 09:30 – 09:45 Economic evaluation of hospital versus nurse-led telephone follow-up after treatment for endometrial cancer Dr Padraig Dixon, School of Social and Community Medicine, University of Bristol 09:45 – 10:00 Comparing the case mix and survival of women receiving breast cancer care from one private provider with other London women with breast cancer Dr Elizabeth Davies, King's College London 10:00 – 10:15 What is the true cost of cervical cancer? A tale of two stories: prevention and diagnosis Mr Robert Music, Jo's Cervical Cancer Trust 10:15 – 10:30 The cost of Cancer in England: Evidence from PatientLevel Data Analysis Dr Mauro Laudicella, City University London 10:30 – 10:45 Stage-based mortality impact of cervical screening Dr Francesca Pesola, Centre For Cancer Prevention, Wolfson Institute of Preventive Medicine, London 10:45 – 11:00 Discussion and Chair’s Closing Remarks Professor Brian Ferguson, Director for Knowledge & Intelligence (Northern and Yorkshire), Public Health England 49 Programme: Wednesday 10 June Session 12 Exhibition Centre Inequalities Chair: Professor Julia Verne, Consultant in Public Health Medicine, Public Health England 09:30 – 09:45 Cancer-specific variation in emergency presentation by sex, age and deprivation across 27 common and rarer cancers Mr Sam Johnson, National Cancer Intelligence Network, Public Health England 09:45 – 10:00 The use of community group peer education models to reduce knowledge barriers in symptoms awareness for over 50s and Bangladeshi population in Camden Miss Sarah Hate, London Cancer, UCLPartners 10:00 – 10:15 Deprivation and Cancer: Does the choice of deprivation metric impact on age standardised incidence and mortality rates across the United Kingdom and the Republic of Ireland? Mr Eamonn O'Leary, National Cancer Intelligence Network 10:15 – 10:30 Findings from a systematic review: ‘Cancer and people with Serious Mental Illness’ Mr James Millman, School of Nursing and Midwifery, Queens University 10:30 – 10:45 Is the deprivation gap for incidence, mortality and survival closing in wales for the most common cancers? Dr Dyfed Huws, Welsh Cancer Intelligence Unit 10:45 – 11:00 Discussion and Chair’s Closing Remarks Professor Julia Verne, Consultant in Public Health Medicine, Public Health England 11:00 – 11:30 Refreshments Grand Ballroom Exhibition & Viewing Poster Finalists 50 Programme: Wednesday 10 June 11:30 –12:40 Exhibition Centre Plenary Session 5: Panel Debate Future challenges for cancer services Chairs: Sir Alex Markham, Director of Research & Professor of Medicine, Leeds Institute of Biomedical & Clinical Sciences and Miss Juliet Bouverie, Director of Services & Influencing, Macmillan Cancer Support Panel: Dr Michael McBride, Chief Medical Officer, Northern Ireland Dr Ruth Hussey, Chief Medical Officer, Wales Dr Gina Radford, Deputy Chief Medical Officer, England Mrs Margaret Grayson, Chair of the Northern Ireland Cancer Research Consumer Forum, and PPI representative on the NI Cancer Trials Centre (NICTC) Executive Dr Kathleen MacLellan, Director of Clinical Effectiveness, Department of Health, Ireland Dr David Dunlop, Senior Medical Officer, Scottish Government Health and Social Care Directorate 12:40 – 13:00 Exhibition Centre Poster Prizes & Close of Conference 13:00 – 14:00 Lunch (packed lunch available on request, must be prebooked) Grand Ballroom Removal of Posters 51 Biographies Juliet Bouverie, Director of Services & Influencing, Macmillan Cancer Support Chair in Plenary Session 5 Juliet Bouverie is Macmillan’s Director of ‘Services and Influencing’ responsible for 650 staff. She holds overall accountability for the development and delivery of Macmillan’s services strategy and for effective influencing of governments and health and social care decision makers across the UK. Juliet has extensive knowledge of health and social care policy in the UK through her 15 years at Macmillan (including 8 years as Head of Policy) and 7 years at the British Red Cross. Prior to her career in the voluntary sector, Juliet worked in parliamentary affairs. Following her own experience as a cancer carer, Juliet chaired the Patient Experience Board for University College London Hospital (UCLH) for 3 years until May 2014. She is a former Trustee of National Voices. Juliet has a degree in Modern Languages in Oxford and lives partly in London and partly in the Forest of Dean. Rachael Brannan Scientific Committee Rachael Brannan joined the National Cancer Intelligence Network in January 2012 following graduating with an MSc in Public Health and Health Services Research from the University of Newcastle Graduate Medical School. This built upon research into the ubiquitin proteasome pathway through her undergraduate degree and a brief stint in student politics as the elected Vice President (Welfare and Equality) of her students’ union. Since January 2014, Rachael has been pivotal in the development of the Public Health England’s Office for Data Release (ODR); ensuring that PHE operates a clear and accountable data release function in which consistent measures are applied to ensure data is processed fairly and lawfully. In January 2015, she took up a new role, as Senior Project Manager within the ODR. Dr David Brewster, Director, Scottish Cancer Registry, Public Health & Intelligence, NHS National Services Scotland Scientific Committee Dr David Brewster graduated in medicine from Bristol University in 1981, moving subsequently to Scotland. After nine years of clinical practice, he entered postgraduate training in public health medicine. In 1995 he was appointed Consultant in Public Health Medicine and Director of the Scottish Cancer Registry. He is also an Honorary Clinical Senior Lecturer 52 Biographies in the Centre for Population Health Sciences at Edinburgh University. He is a member of the Scottish Cancer Taskforce, which oversees the actions outlined in the 2008 policy document, Better Cancer Care, An Action Plan. He has contributed to a variety of national reports, including SIGN cancer guidelines. He has served on the steering committee of the European Network of Cancer Registries (as chairman) and the executive board of the International Association of Cancer Registries. Previously, he was a member of the editorial boards of the European Journal of Cancer and the International Agency for Research on Cancer monograph, Cancer Incidence in Five Continents, volume X. Chris Carrigan, Head of National Cancer Intelligence Network Scientific Committee, Chair in Plenary Session 1 Chris Carrigan is the Director of the National Cancer Intelligence Network (NCIN), operated by Public Health England (PHE); a partnership funded by the public sector and leading cancer charities, tasked with providing new insights and intelligence into cancer inequalities, diagnosis, care, outcomes and experience. Chris’s background includes extensive experience of information management in acute Trusts, primary care, screening services and cancer registries. He has worked on areas of national and international cancer programmes for 10 years. In 2014 Chris was named as one of the Health Service Journal’s Top 50 Innovators in the NHS, and also featured on BBC Radio 4’s Networking Nation series. Professor Michel Coleman, Professor of Epidemiology and Vital Statistics, London School of Hygiene & Tropical Medicine Keynote Speaker in Plenary Session 3 Prof Michel Coleman qualified in medicine in Oxford last century, practising in internal medicine and general practice before deserting to epidemiology. He has worked at IARC (1987-1991): Medical Director of the Thames Cancer Registry (1991-1995); Head of the UK WHO Collaborating Centre on Classification of Diseases (1995-2000); Deputy Chief Medical Statistician at the Office for National Statistics (1995-2004); and Professor of Epidemiology and Vital Statistics at LSHTM (1995-). He leads the CONCORD programme for global surveillance of cancer survival, from which survival trends for 25.7 million patients from 279 registries in 67 countries were published in 2014. 53 Biographies Dr Harry Comber Scientific Committee Dr Harry Comber was Director of the Irish National Cancer Registry from its establishment in 1992 until his retirement in June 2014, and is currently its part-time Interim Director. He graduated from University College, Cork in 1970 with a BSc in chemistry and was awarded a PhD in Biochemistry at the Institute of Cancer Research, London in 1974. He subsequently studied medicine, being awarded an MB in 1978, and worked as a general practitioner and part-time researcher in Ireland from 1984 to 1992. His research interests centre on the use of data to improve cancer control and on the impact of social, psychological and health service factors on cancer stage, treatment and diagnosis. He is currently Deputy Chair of the European Network of Cancer Registries and contributing to the establishment of a European Cancer Intelligence System. Nicky Coombes Scientific Committee Nicky Coombes has worked as the NCIN SSCRG Programme Manager for the past six years. She has wide experience of the public sector gained from working in Local Government, the Voluntary Sector and NHS. She has worked in the health sector for most of her working life, specialising in mental health and cancer services for the last 20 years. She is committed to promoting the voice of the user in public services. Dr David Dunlop Panel Member in Plenary Session 5 By training, Dr Dunlop is a Medical Oncologist and is currently Clinical Director of Specialist Oncology Services and Clinical Haematology for the West of Scotland. Having been Lead Clinician for Chemotherapy Services for NHS Greater Glasgow and Clyde from 2004 to 2009, he then became Clinical Director of the largest regional cancer service in the United Kingdom, involving job planning for over 75 consultant staff. He has recently led a complete re-organisation and reconfiguration of those same cancer services in the West of Scotland. Dr Dunlop has recently been appointed as Senior Medical Officer in the Scottish Government Health and Social Care Directorate with the 54 Biographies oncology portfolio. This role involves national responsibility for strategy, planning and workforce development for cancer services in Scotland. Dr Dunlop sits on the United Kingdom Chemotherapy Board which advises the Chemotherapy CRG in England and Wales. Dr Martin Eatock Chair in Parallel Session 3 Dr Eatock qualified in medicine from the University of Edinburgh and trained in Oncology in Manchester and Glasgow. He took up post as a Consultant and Honorary Senior Lecturer in Medical Oncology in Belfast in 2000 and is an active member of the Upper Gastro-intestinal, Hepatopancreatobiliary and Neuro-endocrine tumour teams. He has clinical and research interests in gastro-intestinal cancer and drug development and is currently chief investigator for a number of national and international clinical trials in upper GI malignancy. Dr Eatock was appointed as Medical Director to the Northern Ireland Cancer Network in 2012 and has overseen the re-development of the Network since then with an expansion in the network site specific groups and the introduction of Peer Review of Cancer MDTs in Northern Ireland. Professor Brian Ferguson, Chief Economist, Public Health England Chair in Parallel Session 11 Prof Brian Ferguson joined PHE having previously been Director of the Yorkshire & Humber Public Health Observatory and Co-Director of the Northern and Yorkshire Cancer Registry & Information Service. Brian was Chair of the UK & Ireland Association of PHOs from April 2006 to March 2011. Within PHE Brian was interim national Director of Knowledge and Intelligence between October 2013 and March 2015. He is now Chief Economist for PHE. Brian has previously held posts as Deputy Director of the Centre for Health Economics, University of York, and was the founding Professor of Health Economics in the University of Leeds. He has served on the National Public Health Career Scientist Award Panel, NICE’s Public Health Interventions Advisory Committee and the Programme Advisory Board of the NIHR Public Health Research Programme. 55 Biographies Dr Gemma Gatta, Research Assitant at the Epidemiology Unit, Instituto Nazionale dei Tumori, Milan Keynote Speaker in Plenary Session 4 Gemma Gatta is cancer epidemiologist, since 2005 is Head of Unit at Evaluative Epidemiology Unit - Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori in Milan. She is the author of over 150 peer reviewed publications in international journals. In recent years she is involved in international population-based research programmes, on survival (EUROCARE), prevalence (EUROPREVAL) and rare cancers (RARECARE and RARECAREnet). She published in Lancet Oncology the last paper on childhood cancer survival in Europe. Dr Anna Gavin Scientific Committee Dr Anna Gavin, a graduate of Queen’s University Belfast Medical School and London School of Hygiene and Tropical Medicine, is a Consultant in Public Health Medicine and Reader within the Centre for Public Health, Queen’s University Belfast. Dr Gavin is the founding Director of the N. Ireland Cancer Registry which this year celebrates its 21st anniversary. She and the registry team has undertaken population based audits of the major cancer sites, work recognised in the awarding of the Queen’s Anniversary prize for further and higher education in 2012. Dr Gavin is seconded one day per week to the National Cancer Intelligence Network of PHE and also Chair of Action and Smoking Health (ASH) Committee for Northern Ireland. She is a member of the executive team of the International Association of Cancer Registries and chair of the scientific committee for this conference. Dr John Graham Chair in Parallel Session 3 Dr John Graham is Director of the National Collaborating Centre for Cancer, which is based in Cardiff and has a contract with the National Institute of Health and Care Excellence (NICE) to produce cancer guidelines. The Centre publishes 3 guidelines per year and each guideline takes 2 years to develop. He also works 3 days per week as a Consultant in Clinical Oncology in Somerset treating breast and urological cancers. 56 Biographies Margaret Grayson, Chair of NICR Research Consumer Forum Scientific Committee, Keynote Speaker in Plenary Session 1, Panel Member Margaret Grayson is Chair of the Northern Ireland Cancer Research Consumer Forum, and PPI representative on the NI Cancer Trials Centre (NICTC) Executive; NICTC Review and Adoption Committee; NI Cancer Trials Network Steering Group and Belfast Cancer Research UK Centre Governance Board. She has been involved in partnering with researchers since 2010, including membership of study steering groups; HSC R&D Division PPI Group and working with the NI Cancer Registry. Margaret represents NI on the NCRI PPI Steering Group and a member of the CLG. She is an Involvement Coach with Cancer Research UK; a trained facilitator with Macmillan Building Research Partnerships and a member of Independent Cancer Patients’ Voice. Dr Tom Grew, Patient Representative Keynote Speaker in Plenary Session 4 Tom Grew is a 30 year old academic foundation doctor originally from south Derbyshire in England. Currently working near Slough and in Oxford he has represented teenagers and young adults with cancer for a number of years. Inspired by his own experience of cancer at the age of 18 he has gone on to study medicine alongside working in various areas of cancer research as a patient representative. Professor Willie Hamilton, Professor of Primary Care Diagnostic, University of Exeter Keynote Speaker in Plenary Session 2 Professor Willie Hamilton, MD, FRCP, FRCGP, is professor of primary care diagnostics at the University of Exeter, UK and a practising GP. His cancer diagnostic research centres on the symptomatic patient in the consulting room, identifying relevant symptoms of cancer, and quantifying the risk they pose. The most visible outputs of this work are the Risk Assessment Tools, which describe the risk of cancer with symptom combinations. These are available in several formats, including integrated forms for GP clinical computers. He was the clinical lead on the revision of NICE guidance on investigation of suspected cancer, published in May, 2015. 57 Biographies Professor Mike Hawkins, Professor of Epidemiology Public Health, University of Birmingham Keynote Speaker in Plenary Session 4 Mike Hawkins is Professor of Epidemiology and Director of the Centre for Childhood Cancer Survivor Studies at the University of Birmingham, UK. His main research interests relate to health and social outcomes among survivors of cancer treated under the age 40 years. He is UK Principal Investigator for three international collaborative studies PanCareSurFup, PROCARDIO and CEREBRAD which are each funded by the European Commission under FP-7. These studies are concerned with the risks and causes of subsequent primary cancers, serious heart disease and strokes after cancer when young. His research team established, and continue a programme of investigations relating to, the British Childhood Cancer Survivor Study which relates to the cohort of 35,000 individuals diagnosed with cancer before aged 15 years, between 1940 and 2006, in Britain, and who survived at least 5 years. Also the Teenage and Young Adult Cancer Survivor Study which relates to 235,000 individuals diagnosed with cancer when aged 15 to 39 years, between 1970 and 2006, in England and Wales and who survived at least 5 years. www.bccss.bham.ac.uk He is a current, or recent, member of: the NCIN – Children, Teenagers and Young Adults – Site Specific Clinical Reference Group; the NCRI – Children’s Cancer and Leukaemia – Clinical Studies Group; the NCRI – Teenage and Young Adult – Clinical Studies Group. Sara Hiom, Director, Cancer Research UK Keynote Speaker in Plenary Session 3 Sara Hiom trained and worked in biomedical research before joining Cancer Research UK in 2000. She has built expertise, created and led teams within the charity in health evidence, evaluation, prevention, early diagnosis, primary care, health community engagement and more recently for information across the patient pathway. Now with responsibility for health professional audiences, early diagnosis strategy and cancer intelligence across the charity, the focus is very much on understanding how we can improve survival and realise CR-UK’s ambition that 3 in 4 people will survive cancer within the next twenty years. Sara has worked closely with partners leading NAEDI and continues to champion early diagnosis, from evidence to practice, with a key new initiative being the ‘ACE’ Programme 58 Biographies Dr Ruth Hussey, Chief Medical Officer, Wales Panel Member in Plenary Session 5 Dr Ruth Hussey OBE, was born and brought up in North Wales. After qualifying as a doctor Ruth worked in a variety of public health leadership roles in North West England, including academia and the NHS. More recently she worked in the UK Department of Health before becoming Chief Medical Officer for Wales in 2012. Ruth has been committed to reducing health inequalities throughout her working life. She established a strong partnership based approach to this work in North West England and is an advocate of integrated approaches to improving health and delivering high quality health and social care. She has a strong commitment to public involvement in their health and health care as well as supporting effective clinical leadership to ensure the development of innovative approaches to meet 21st century health challenges. She is involved in public health legislation and developing ‘prudent healthcare’ in Wales to support a sustainable health system. Dr Dyfed Huws Scientific Committee Dr Dyfed Huws, Director of the Welsh Cancer Intelligence and Surveillance Unit, helping turn data in to useful health intelligence for cancer prevention and improved services. Dyfed leads a programme of continuously improving data sources and the usefulness of analysis outputs as part of the Registry’s statutory duties. He is a public health physician who qualified in medicine from Cardiff, worked in respiratory medicine and neurology, and while specialising in public health he studied at the London School of Hygiene & Tropical Medicine. He has worked in Wales and England and with the WHO Euro in Copenhagen and has conducted projects across Europe and Africa . His other interests include road cycling and singing but now he’s busy with his young sons. Dr Robin Ireland Chair in Parallel Session 4 Robin Ireland is a Consultant Haematologist at King’s College Hospital and the Lead Clinician for the King’s Haematological Malignancy Diagnostic Centre (KHMDC) which provides specialist diagnostic services for haematological cancers and bone marrow failure syndromes to a population of approximately 5.3 million in Southeast England. 59 Biographies He is a practicing clinician in a department which has a strong research base with particular interests in the Myelodysplastic Syndromes, Aplastic Anaemia, Chronic Lymphocytic Leukaemia, Lymphoma and Myeloma. Since 2013 he has been Chair of the Haematology Specialist Clinical Reference Group of the National Cancer Intelligence Network - Public Health England and has been particularly involved with the development and implementation of the Cancer Outcomes and Service Dataset. Professor Patrick Johnston, Vice-Chancellor, Queen’s University Belfast Chair in Plenary Session 3 Professor Patrick Johnston is President and Vice-Chancellor of Queen’s University Belfast. He received his medical degree with distinction from University College Dublin in 1982, followed by his MD and PhD in Medicine and a Fellowship in Oncology at the National Cancer Institute (NCI USA). He joined Queen’s University in 1996 as Professor of Oncology, later leading the establishment of the Centre for Cancer Research and Cell Biology and becoming its Director. In 2007 Professor Johnston was appointed Dean of the School of Medicine, Dentistry and Biomedical Sciences. His research focus has been on the understanding of mechanisms of drug resistance in gastrointestinal cancers. Professor Johnston has received many national and international awards, is a Fellow of the Academy of Medical Sciences and in 2013 and he was named winner of the international Bob Pinedo Cancer Care Prize. Among other influential roles, he serves on the Board of the Medical Research Council and was appointed Chair of the Medical Research Council Translational Research Group in 2012. He is the founder and Co-Chair of the Society for Translational Oncology. Roger Kockelbergh Chair in Parallel Session 7 Roger qualified in 1983 from Birmingham University. He trained in general surgery then urology in the East Midlands and Norfolk. His research leading to an MD thesis on bladder cancer was performed in Nottingham and he was appointed as a Lecturer at the University of Melbourne in renal transplantation and urology. He has been a Consultant in Uro-Oncology in Leicester since 1996. He has been Clinical Director, Secretary and Chairman of the BAUS Section of Oncology, National Clinical Lead for Urological Cancer and Chairman of the NCIN SSCRG. 60 Biographies Dr Yoryos Lyratzopoulos Scientific Committee, Chair in Parallel Session 1 Yoryos is a public health medicine academic who specialises in the epidemiology of cancer healthcare and cancer health services research. His research focuses on the timeliness of cancer diagnosis in symptomatic patients, and the understanding person- and organisational-level variation in cancer patient experience. He has been NIHR Post-Doctoral Fellow 20122104, moving to University College London as a Reader in Cancer Epidemiology in 2015, supported by a Cancer Research UK Clinician Scientist Fellowship. Dr Kathleen MacLellan, Director of Clinical Effectiveness, Department of Health, Ireland Panel Member in Plenary Session 5 Dr Kathleen Mac Lellan is Director of Clinical Effectiveness, Department of Health. She leads the clinical effectiveness policy function and heads the Clinical Effectiveness Unit in the Department of Health. This unit supports the National Clinical Effectiveness Committee (NCEC) to promote evidencebased healthcare through quality assured clinical effectiveness processes. Professor Jane Maher Chair in Parallel Session 8 Professor Jane Maher trained at King’s College London, Westminster Medical School, Harvard University/Massachusetts General Hospital and The Royal Marsden Hospital. She has worked as a consultant clinical oncologist at Mount Vernon Cancer Centre for more than 20 years. Between 1986 -1999, she developed both general oncology services for five separate hospitals and specialist head and neck cancer services for three health regions. Since 1999, she has focused her clinical activity on breast and advanced prostate cancer to enable her to work with Macmillan Cancer Support as Chief Medical Officer and with the NHS as a clinical leader; most recently with NHS Improvement as a National Clinical Advisor for Aftercare and Survivorship. 61 Biographies Chair: Sir Alex Markham, Director of Research & Professor of Medicine Chair in Plenary Session 5 Professor Markham has made various contributions to medical science, is a Physician and Pathologist, and trained initially in medicinal chemistry. His commercial experience includes cancer drug development and introduction of DNA Fingerprinting for medico-legal applications (Queen’s Award for Technological Achievement in 1990). A Fellow of the Academy of Medical Sciences, he served as Chairman of the National Cancer Research Institute (NCRI) establishing the National Cancer Intelligence Network, and has been a member of the UK Clinical Research Collaboration Board and the National Institute of Health Research Advisory Board. He was a member of the Government’s Cancer Reform Strategy Advisory Board, has chaired numerous MRC and Wellcome Trust Committees and was a Trustee of Arthritis Research UK. He chaired the Translational Medicine Board for MRC and NIHR under the auspices of OSCHR, and was SRO for the NIHR Research Capability Programme. Professor Markham was Chief Executive of Cancer Research UK until 2008. He received a knighthood in the 2008 New Year’s Honours for services to medicine. Dr Michael McBride, Chief Medical Officer, Department of Health, Social Services & Public Safety N. Ireland Welcome Note in Plenary Session 1, Panel Member in Plenary Session 5 Dr Michael McBride was appointed Chief Medical Officer for the N. Ireland Department of Health, Social Services and Public Safety in 2006. Previously he was Medical Director at the Royal Group of Hospitals. Dr McBride graduated with Distinction from Queen’s University Belfast in 1986 and completed his undergraduate and postgraduate training in Northern Ireland. In 1991 he attained a Research Fellowship at St Mary’s Medical School and Imperial College London, researching new drug treatments for HIV. He was appointed Consultant Physician in HIV medicine at the Royal Group of Hospitals and has over 10 years health service management experience. He has a longstanding interest in continuing medical education and was Postgraduate Clinical Tutor in the Royal Group of Hospitals between 1996 and 2000 and Director of Education in the Royal Hospitals from 2000. Dr McBride has been closely involved in the development of the new Health & Social Care structures post Review of Public Administration, including the establishment of the Public Health Agency. 62 Biographies Dr Martin McCabe, Chair Childhood Site Specific Clinical Reference Group of NCIN Chair in Plenary Session 4, Chair in Parallel Session 6 Dr McCabe studied medicine at the University of Cambridge (1994), followed by clinical training in paediatrics and subsequently paediatric oncology within the Wessex, North East and Anglia deaneries, and a year in Melbourne, Australia. After completing a PhD in medulloblastoma genetics (Cambridge, 2009) he was appointed in 2009 as a clinical senior lecturer at the University of Manchester and an honorary consultant in adolescent and young adult cancer at the Christie Hospital, Manchester. Dr McCabe has a translational research programme in brain tumours and sarcomas of children and young people that combines laboratory-based research and clinical trials. In 2011 he joined the NCIN clinical reference group for children and young people and has chaired the group since 2013. Professor Henrik Møller Chair in Parallel Session 9 Henrik Møller is Professor of Cancer Epidemiology at King’s College London School of Medicine, and Director of Cancer Epidemiology and Population Health in King’s Health Partners Cancer Centre. He was a Director at the Thames Cancer Registry in King’s College London from 2000 to 2011. Previous employments were as Director of Centre for Register-based Research at the Danish National Research Foundation in Copenhagen (1995-1999); as Scientist and Acting Unit Chief in Unit of Carcinogen Identification and Evaluation at International Agency for Research on Cancer in Lyons (1992-1995); and as Epidemiologist at the Danish Cancer Registry in Copenhagen (1986-1992). Henrik Møller has honorary associations with several medical schools in England and Denmark. He has published 300+ peer reviewed research articles in cancer epidemiology and health services research. Dr Peter Murchie Keynote Speaker in Plenary Session 2 Dr Peter Murchie trained in medicine at the University of Aberdeen, graduating in 1994. He completed vocational training in general practice in Northeast Scotland before embarking upon a career in academic general practice through a Cancer Research UK Primary Care Oncology Fellowship. He is currently Senior Clinical Lecturer in Academic Primary Care, University of Aberdeen. He leads a research 63 Biographies programme which uses clinical data to pursue two main aims: first to better understand the cancer diagnostic pathway within primary care, and second, to improve community-based cancer survivorship care. He maintains a foothold in daytime and out-of-hours general practice in Northeast Scotland. Professor Liam Murray Chair in Parallel Session 10 Liam Murray, Acting Director of the Centre for Public Health, Queen’s University Belfast is a clinical academic and leads the QUB Cancer Epidemiology & Health Services Research Group. Professor Murray has a particular interest in cancers of the gastro-intestinal tract and is PI of an all-Ireland case-control study of oesophageal adenocarcinoma and the NI Barrett’s Register. He also has a major interest in pharmaco-epidemiological studies in the cancer field and has recently published in this area. He has over 200 publications in international scientific journals. Professor John Newton Chair in Parallel Session 5 Professor John Newton is Chief Knowledge Officer of Public Health England and Honorary Professor of Public Health and Epidemiology at the University of Manchester. He has more than twenty years experience in public health in academic, professional and senior management roles. As well as being an epidemiologist in the University of Oxford he has been Director of Research and Development for the NHS in Southampton and Oxford and was the first Director and CEO of UK Biobank. Professor Joe O’Sullivan Chair in Parallel Session 7 Joe O’Sullivan is Clinical Director of the Northern Ireland Cancer Centre, Belfast and Professor of Radiation Oncology at the Centre for Cancer Research and Cell Biology, Queen’s University Belfast. He graduated from University College Dublin medical School, trained in Radiation Oncology in St. Luke’s Hospital in Dublin, and the Royal Marsden London. He was appointed as a senior lecturer and consultant clinical oncologist to Queen’s University Belfast in 2004 and as Professor of Radiation Oncology in 2011. His research interests include bone-seeking radionuclide therapy in 64 Biographies metastatic prostate cancer, translational research in prostate cancer and radiotherapy. He is one the 4 Directors of the FASTMAN Prostate Cancer Centre of Excellence (Belfast and Manchester) which is 5 year programme of research awarded in 2014 and funded by Movember and PCUK. Dr Mick Peake, National Clinical Lead, NCIN, PHE Scientific Committee, Keynote Speaker in Plenary Session 1 Dr Mick Peake, Clinical Lead for the National Cancer Intelligence Network (NCIN), within PHE is also Honorary Consultant and Senior Lecturer in Respiratory Medicine for the University Hospitals of Leicester. He has been involved in the development and implementation of national cancer policy in the UK since the late 1990s for over thirty years with major interest in lung cancer and mesothelioma. He is co-clinical Lead for the National Lung Cancer Audit (NLCA), run by the Royal College of Physicians, where he is Associate Director of the Clinical Effectiveness and Evaluation Unit. He was National Clinical Lead for NHS Cancer Improvement, with a particular remit for Lung Cancer plus the National Awareness and Early Diagnosis Initiative (NAEDI). He is member of the steering group of the British Thoracic Oncology Group, chair of Mesothelioma UK, sits on the National Cancer Research Institute’s Lung Clinical Study Group and is a member of the Government’s National Advisory Group for Clinical Audit and Enquiries. He has published widely on early diagnosis and improving outcomes for cancer patients by proper service configuration, supported by good clinical outcome data. Prof Sir Richard Peto, Professor Professor of of Medical Medical Statistics Statistics &&Epidemiology Epidemiology Keynote Speaker in Plenary Session 3 Sir Richard Peto is Professor of Medical Statistics and Epidemiology at the University of Oxford. He and his colleagues have conducted epidemiological studies of smoking, drinking, adiposity and blood pressure in many different countries, demonstrating the current and the future size of the epidemic of death from tobacco. They have now established a worldwide network of large prospective and retrospective studies to monitor the evolution of the epidemic over the next few decades. Their results are widely used throughout the world to help limit mortality from tobacco. He was knighted in 1999 for services to epidemiology. 65 Biographies Dr Gina Radford, Deputy Chief Medical Officer, England Panel Member in Plenary Session 5 Dr Gina Radford is Deputy Chief Medical Officer for England, where she has a particular focus on public health and health improvement. She has had a substantial career in public health, most recently working in Public Health England providing national leadership in the Ebola response, an issue she continues to cover on behalf of CMO within the Department of Health. She has had a long interest in the area of Cancer and has contributed at both national and regional levels, including undertaking the evaluation of the pilot of the Be Clear on Cancer initiative on bowel cancer’. Dr Jem Rashbass, National Director for disease registration at Public Health England Keynote Speaker in Plenary Session 1, Chair in Parallel Session 2 Dr Jem Rashbass studied medicine at University College London, trained in diagnostic pathology, becoming a clinical academic dividing his time between clinical work and the creation of Clinical and Biomedical Computing Unit at Cambridge University. In 2003 he became head of the Eastern Cancer Registry and Information Centre, a post he held in conjunction with the leadership of the East of England Cancer Screening Quality Assurance Service. In April 2013 he became National Director for Disease Registration in PHE and is responsible for the 220 staff in the National Cancer Professor Greg Rubin, Professor of General Practice and Primary Care, Durham University Chair in Plenary Session 2 Greg Rubin is Professor of General Practice and Primary Care in the School of Medicine, Pharmacy and Health at Durham University, UK, and directs its Evaluation, Research and Development Unit. His research interests lie in the diagnosis and management of significant disease in primary care and at the interface with secondary care, with a substantial programme of research and development on the early diagnosis of cancer. He is also part of the Policy Research Unit for Cancer Awareness, Screening and Early Diagnosis. Until 2014, he was the Royal College of General Practitioners / Cancer Research UK Clinical Lead for Cancer. 66 Biographies Dr Isabelle Soerjomataram, Section of Cancer Surveillance, International Agency for Research on Cancer Keynote Speaker in Plenary Session 3 Isabelle Soerjomataram is a medical epidemiologist with research interest in international variation in the burden of cancer, impact of prevention on cancer, new cancer indicators and impact of cancer on healthy ageing. She received her medical degree from the University of Indonesia in 2001, followed by a PhD in cancer epidemiology with a thesis on the epidemiology of multiple cancers at Erasmus Medical Centre (2007). Before moving to the International Agency for Research on Cancer, she went to the Harvard School of Public Health as Visiting Scholar under a personal fellowship from the Dutch Scientific Foundation. Professor Robert JC Steele, Professor of Surgery & Head of Cancer Research, University of Dundee Keynote Speaker in Plenary Session 1 Professor Robert JC Steele did his initial surgical and academic training in Edinburgh, Hong Kong and Aberdeen and was appointed as Senior Lecturer in Surgery at the University of Nottingham in 1990. He was then appointed Professor of Surgical Oncology at the University of Dundee in 1996 and as Professor of Surgery and Head of the University Department of Surgery in 2003. His main interest is colorectal cancer and he is Director of the Scottish Colorectal Cancer Screening Programme, having acted as clinical lead for the UK demonstration pilot that was used to inform the decision to introduce national bowel cancer screening programmes throughout the UK. He chaired the SIGN group that developed the latest set of colorectal cancer guidelines. He is currently a member of Council of the Royal College of Surgeons of Edinburgh and the editor of “The Surgeon”. He also chairs the Board of Directors of the Scottish Cancer Foundation and is President Elect of the Association of Coloproctology of Great Britain and Ireland. Richard Stephens, Stephens Chair of NCRI’s Liaison Group (CLG) Scientific Committee, Chair in Plenary Session 3 Richard Stephens, a survivor of two cancers and a heart emergency has participated in clinical trials and research studies, and currently serves on two trial steering groups delivering or monitoring specific research studies. As a patient advocate and representative, his formal roles 67 Biographies including chairing NCRI’s Consumer Liaison Group (CLG) and NIHR Cancer Network’s Patient and Public Involvement Steering Group and co-chairing the Advisory Group for NIHR’s Dissemination Centre. Richard is leading a novel partnership with Astra Zeneca, setting up an independent Patient Panel, to bring patients and the company’s researchers together to discuss trial design and recruitment methods. He is joint Editor-In-Chief of BMC’s online open access Journal of Research Involvement and Engagement. He is a co-author of 2012’s Action On Access, an influential consumer-led report recommending organisational and cultural changes to encourage and support more patients to participate in research. He is one of the consumers who helped design the English National Cancer Patient Experience Survey’s questions on research awareness and participation. Julia Verne Scientific Committee, Chair in Parallel Session 12 Julia Verne is Public Health England’s (PHE) strategic public health lead for the National Cancer Intelligence Network and also the Clinical Lead for PHE’s National End of Life Care Intelligence Network having had a longstanding interest in cancer and end of life care epidemiology. She is a Consultant in Public Health Medicine and has been involved in work to improve cancer patient outcomes since 1996. She is currently chairing the NICE Bladder Cancer Guidance Development Group (GDG) and previously chaired the NICE Skin Cancer Service GDG. Julia is a Visiting Professor at the University of the West of England in the Faculty of Business and Law and is currently studying for a second PhD entitled ‘Autonomy and Paternalism in End of Life Care for Elderly Patients’. Professor Hamish Wallace, Consultant Paediatric Oncologist, RHSC Keynote Speaker in Plenary Session 4 Professor Hamish Wallace is a Consultant in Paediatric Oncology at the Royal Hospital for Sick Children in Edinburgh and Honorary Professor at the University of Edinburgh. His main research interests are in fertility prediction and preservation for young cancer patients, Hodgkin lymphoma and mathematical modelling of biological systems. He is a founding member of the International Society for Fertility preservation (ISFP), was Chair of the UK Children’s Hodgkin’s Lymphoma Working Group (2002-13) and President of the European Network for Paediatric Hodgkin’s Lymphoma (2007-13). Hamish was the Registrar of the Royal College of Paediatrics & Child Health from 2012-13 and a former Trustee of the children’s cancer charity CLIC Sargent (2010-12). He directs the HEBA Research Centre in Edinburgh, which is committed to ongoing research into the long-term 68 Biographies effects of the treatment of childhood cancer and is a co-author of over 170 peer-reviewed publications (h index 50), and four books. Hamish is the co-founder and organiser for ESLCCC, a biannual International conference on the late effects of the treatment of childhood cancer. Professor David Weller, Head of Cancer and Primary Care Research International Network (Ca-PRI) Keynote Speaker in Plenary Session 2 Professor David Weller graduated from the University of Adelaide in 1982, and undertook GP and public health training in the UK and Australia (including the MPH at University of Adelaide, 1989-90). After senior lecturer posts in Australia he moved to Edinburgh in 2000, where he is the James Mackenzie Professor of General Practice. He was Head of School from 2005-2012 and is currently Director for taught Masters programmes in the medical school. His research is mainly in cancer prevention and management, and he leads the Cancer and Primary Care Research International Network (Ca-PRI). David sits on various Scottish and UK cancer advisory boards. Roger Wilson CBE, Hon President Sarcoma UK Chair in Plenary Session 2 Roger Wilson is a former TV producer and journalist. He was diagnosed with a soft tissue sarcoma in 1999 and has had six recurrences. He started as a patient advocate in cancer research in 2002 and served on the board of the NCRI. He was a Steering Group member of the Cancer Reform Strategy which recommended the creation of NCIN and he is still a member of the SSCRG for Sarcoma. He has chaired a number of national groups in survivorship, prevention and supportive/ palliative care. In 2003 he founded Sarcoma UK, now a national UK charity with full-time staff. In 2009 he was a co-founder of Sarcoma Patients Euronet. Roger has also worked with EORTC and ECCO. He was appointed CBE in 2011 and has received honorary degrees from the Universities of Lancaster and Sheffield. 69 Biographies James Wong Scientific Committee James Wong is a Consumer Representative of the Scientific Committee for the National Cancer Intelligence Network (NCIN) Cancer Outcomes Conference 2015. He is also a Consumer Representative of the NCIN Scientific Advisory Group. James was most recently an investment manager at a venture capital fund, where he focused on investments in medical technology companies and also served in a number of board director and observer roles. Prior to that, he advised corporate and financial clients on strategy and due diligence engagements in healthcare and technology industries. A graduate of Royal Holloway, University of London, and University of Cambridge, James holds degrees in Biochemistry and Computational Biology. He also completed the Management of Technology and Innovation programme at Cambridge Judge Business School. 70 Did you know… …Shorts Aircraft Factory pioneered Vertical Take Off and Landing (VTOL) aircrafts in the 50’s. Sir James Martin a native of Co Down, invented the aircraft ejector seat? …that Joseph Black, (1728-1799) son of a Belfast wine merchant discovered carbon dioxide and his principles were used by James Watt to develop the steam engine (1775)? …that Belfast’s Crown Bar was the first pub ever owned by the National Trust (1978)? … Samuel Beckett, Novel Laureate schooled in Co Fermanagh, taught languages at Campbell College, Belfast. As an accomplished cricketer, he became the only Nobel laureate to have an entry in Wisden Cricketers' Almanack, the "bible" of cricket. 71 Posters P-01. What factors influence smoking behaviour in young females? Robert Atenstaedt1, 3, Kelly Evans2, Nikki Lloyd-Jones3 1 Public Health Wales, 2Social Change Ltd, 3Institute of Health, Medical Science and Society, Glyndŵr University P-02. Socioeconomic inequalities in cancer incidence in the West of Scotland:20102012 compared to 2000-2002. Philip McLoone1, Emily Tweed2, David Morrison1 1 West of Scotland Cancer Survellance Unit, University of Glasgow, 2Public Health, University of Glasgow P-03. HPV vaccine acceptance in males Gillian Prue1, Olinda Santin1 1 School of Nursing and Midwifery, Queen's University Belfast P-04. The fraction of cancers attributable to tobacco in Wales, in 2012 Casey Dunlop1, Katrina Brown1, Ceri White2, Dyfed Huws2, Nick Ormiston-Smith1 1 Statistical Information Team, Cancer Research UK, 2Welsh Cancer Intelligence and Surveillance Unit P-05. How can the Scottish Government Detect Cancer Early programme contribute to a reduction in health inequalities? Nicola Barnstaple1, David Linden1, Daniel Hawksworth1, Scott Taylor1 1 Scottish Government P-06. The impact of the Scottish Government Detect Cancer Early programme on uptake of bowel screening Nicola Barnstaple1, David Linden1, Daniel Hawkswort1h, Scott Taylor1, Di Primrose1, Jill Walker1 1 Scottish Government P-07. Can a social marketing campaign have an impact on early stage breast cancer diagnoses? Nicola Barnstaple1, David Linden1, Daniel Hawksworth1, Scott Taylor1, Jill Walker1 1 Scottish Government P-08. Ethnicity, deprivation and screening: an analysis of survival from breast cancer among screening-eligible women in the West Midlands diagnosed from 1989 to 2011 Melanie Morris1, Laura Woods1, Nicola Rogers2, Emma O'Sullivan2, Olive Kearins2, Bernard Rachet1 1 London School of Hygiene and Tropical Medicine, 2West Midlands Breast Screening Quality Assurance Reference Centre 72 Posters P-09. Cancer Screening Programmes – public knowledge and beliefs in Northern Ireland Diane Anderson1, Adele Graham 1, Conan Donnelly2, Margaret McCrory1 1 Public Health Agency, 2N. Ireland Cancer Registry, Centre for Public Health, Queen’s University Belfast P-10. Stage at diagnosis and early mortality from cancer in England Sean McPhail1, Sam Johnson1, David Greenberg2, Mick Peake1, Brian Rous2 1 National Cancer Intelligence Network, 2National Cancer Registration Service P-11. Comparing cancer survival by stage in London Vivian Mak1, John Broggio2 1 National Cancer Intelligence Network, 2Knowledge & Intelligence Team - West Midlands P-12. Implementation of secondary prevention programs in Setif, Algeria Ettore Bidoli1, Diego Serraino1, Abbes Mahnane2, Slimane Laouamri2, Zoubida Zaidi2, Hafida Boukharouba2, Lamia Kara2, Silvia Birri1, Paolo De Paoli1, Mokhtar Hamdi Cherif2 1 Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico, IRCCS, 2 Faculty of Medicine, University of Setif P-13. Barriers and motivators to participation in the Northern Ireland Breast and Cervical Screening Programmes: a qualitative study Diane Anderson1, Tracy Owen1, Adrian Mairs1, Colin McMullen1, Adele Graham 1 1 Public Health Agency P-14. Men’s experience of a prostate biopsy is associated with health-related quality of life Frances Drummond1, Finian Bannon2, Heather Kinnear2, Anna Gavin2, Linda Sharp1,3 1 National Cancer Registry Ireland, 2 N. Ireland Cancer Registry, Centre for Public Health, Queen’s University Belfast, 3Newcastle University P-15. Analysis of early stage of diagnosis of cancer and survival Carina Crawford1, Nick Ormiston-Smith1 1 Cancer Research UK P-16. Improvements in factors related to early diagnosis and survival in Colorectal and Lung cancer Isabella Carneiro1, Nick Ormiston-Smith2, Lucy Ellis-Brooks1, Mick Peake1 1 NCIN, 2Statistical Information Team, Cancer Research UK [CRUK] P-17. MiR205 is a p53/p63-dependent marker lost in poor outcome Triple Negative Breast Cancers Ezanee Azlina Mohamad Hanif1, 2, 3, Richard Kennedy1, Paul Mullan1 1 Centre for Cancer Research and Cell Biology(CCRCB), Queen’s University of Belfast, 2UKM Medical Molecular Biology Institute (UMBI), 3National University of Malaysia (UKM) 73 Posters P-18. Immunological faecal occult blood testing: Can a test using digital recta examination alone diagnose colorectal cancer? Jennie Grainger1, Paul Skaife1 1 University Hospital Aintree P-19. Challenges in measuring the diagnostic and treatment interval within Northern Ireland; ICBP module 4 Therese Kearney1, Kerry Moore1, Conan Donnelly1, Anna Gavin1 1 N. Ireland Cancer Registry, Centre for Public Health, Queen’s University Belfast P-20. A single centre feasibility study examining the efficacy of annual reminders to facilitate uptake in Bowel Scope Screening non-attenders Robert S Kerrison1, Lesley M McGregor1, Sarah Marsha2, John Isitt3, Jane Wardle1, Christian Von Wagner1 1 Health Behaviour Research Centre, Department of Epidemiology and Public Health, University College London, 2St Marks Bowel Cancer Screening Centre, St Marks Hospital, Watford Road, 3Resonant Behaviour Change and Social Marketing P-21. Increasing early detection of lung cancer: Pilot Chest xray self referral for symptomatic patients (Southern Trust- N. Ireland). Interim Results Rory Convery1, Naomi Chapman1, Stephen Hall2, Gerry Millar3 1 Respiratory Medicine, Craigavon Hospital, SHSCT, 2Radiology, Craigavon Hospital, SHSCT, 3GP Macmillan Facilitator SHSCT P-22. Cancer Treatment Helpline – a national 24/7 triage service for NHS Scotland Scott Taylor1, Michelle Higgins2 1 Scottish Government, 2NHS24 P-23. Multidisciplinairy breast cancer registry: improvement of quality of care through the NABON Breast Cancer Audit Sabine Siesling1,2, Annelotte van Bommel3, Marie-Jean Vrancken Peeters4, Michiel Wouters4, Ruud Pijnappel5, Marc Mureau6, Agnes Jager6, Pauline Spronk7, Kay Schreuder1, Thijs van Dalen8 1 Netherlands Comprehensive Cancer Organisation (IKNL), 2University of Twente, 3 Leiden University Medical Centre, 4Netherlands Cancer Institute / Antoni van Leeuwenhoek Hospital, 5University Medical Centre Utrecht, 6Erasmus MC Cancer Institute, Rotterdam, 7Dutch Institute for Clinical Auditing (DICA), 8Diakonessenhuis P-24. Development of a Chemotherapy Capacity Calculator Tool: An NHS & Pharmaceutical Industry Joint Working Partnership Steve Williamson1, Alison Featherstone1, Gracy Crane2, Carol Hawkes2, Theresa Marshall3, Craig Davidson3 1 North of England Cancer Network, 2GSK UK Limited, 3Novartis Pharmaceuticals 74 Posters P-25. Radiotherapy Skin Care Guidance Rachel Harris1, Charlotte Beardmore1, Heidi Probst2, Gemma Burke2, Sarah James1, Amanda Bolderston3 1 The Society and College of Radiographers, 2Sheffield Hallam University, 3British Columbia Cancer Agency P-26. New evidence for workforce planning: 470 specialist adult cancer nurses who cover Cancer of Unknown Primary (CUP) in hospitals in the UK Rachel White1, Jacqueline Goodchild1 1 Macmillan Cancer Support P-27. One year survival for cancer diagnosed following emergency presentation. An update from the London Cancer A&E audit Neil Chauhan1,2, Melanie Ridge1, Michael Parker3, Mairead Lyons1, Kathy PritchardJones1 1 London Cancer, 2Barts Health NHS Trust, 3Anglia Ruskin University P-28. Cancer diagnosed following emergency presentations at three sites in one Trust. Detailed analysis from the London Cancer A&E audit leading to quality improvement. Neil Chauhan1,2, Tania Anastasiadis3, Sarah Slater2, Melanie Ridge1, Mairead Lyons1, Kathy Pritchard-Jones1 1 London Cancer, 2Barts Health NHS Trust, 3Tower Hamlets Clinical Commisioning Group P-29. New evidence for workforce planning: 3,600 specialist adult cancer nurses in hospitals in the UK Rachel White1, Jacqueline Goodchild1 1 Macmillan Cancer Support P-30. Clinical Headline Indicators a.k.a. COSD Level 4 Karen Linklater1, Jackie Charman2, Lucy Elliss-Brookes3, Kenny Lee1, Christopher Almond1, Barry Plewa1, Stephen Raynor1, Michael Peake3 1 Public Health England, National Cancer Registration Service (London), 2Public Health England, Knowledge and Information Team (West Midlands), 3Public Health England, National Cancer Intelligence Network P-31. Method for finding the organisation code of first trust visited in the English National Cancer Registration dataset Karen Linklater1, Jackie Charman2 1 Public Health England, National Cancer Registration Service (London), 2Public Health England, Knowledge and Information Team (West Midlands) P-32. Lung cancer services in London Karen Linklater1, Stephen Scott2 1 Public Health England, National Cancer Registration Service (London), 2London Cancer Alliance 75 Posters P-33. The Role of the Multidisciplinary Team (MDT) in the management of early stage endometrial cancers diagnosed outside the regional cancer centre in Northern Ireland : a 5 year review Meabh Cosgrove1, Stephen Dobbs2, Ian Harley3, Hans Nagar4, John Price5 1 Department of Gynaecological Oncology, Belfast City Hospital, 2Department of Gynaecological Oncology, Belfast City Hospital, 3Department of Gynaecological Oncology, Belfast City Hospital, 4Department of Gynaecological Oncology, Belfast City Hospital, 5Department of Gynaecological Oncology, Belfast City Hospital P-34. Making raw PAS, PATH and MDT data feeds meaningful Karen Linklater1, Karen Graham 1 1 Public Health England, National Cancer Registration Service (London) P-35. An electronic tool for aiding the clinical trial referral process Richard Clapham 1, Andrew Wardley1, Thomas Thornber1, Matthew Barker-Hewitt1, Jacqueline Livsey1, Catherine O'Hara1 1 The Christie NHS Foundation Trust P-36. Modernising the provision of prostatic surgical services Eileen Kesson1, David Morrison2, Gwen Allardice1, Iain Wallace3 1 NHS Greater Glasgow and Clyde Health Board, 2University of Glasgow, 3NHS Lanarkshire Health Board P-37. Projections of urgent GP referrals for suspected cancer until 2019/20 in the East Midlands Marta Emmett1, Carolynn Gildea1, Jason Poole1 1 PHE - East Midlands Knoweledge and Intelligence Team P-38. Quality metrics for evaluation of new Multidisciplinary Diagnostic Centres Donna Chung1, Andrew Millar1,2, Claire Levermore3, Mairéad Lyons1, Kathy PritchardJones1 1 London Cancer, UCLPartners, 2North Middlesex University Hospital NHS Trust, 3 University College Hospitals NHS Foundation Trust P-39. Stereotactic Ablative Body Radiotherapy for Early Stage Lung Cancer – A Business case and outcomes Audit, NICC, Belfast Sai Jonnada1, Gerry Hanna1, Jonathan McAleese1 1 NICC, Belfast City Hospital P-40. Personal and Public Involvement in Cancer Registry Research – The Northern Ireland Model Margaret Grayson1, Ruth Boyd2, Anna Gavin3, Conan Donnelly3 1 Northern Ireland Cancer Research Consumer Forum, 2Northern Ireland Cancer Trials Centre, 3 N. Ireland Cancer Registry, Centre for Public Health, Queen’s University Belfast, 76 Posters P-41. The experiences of people living with cancer (plwc) when undergoing care transitions Jon Ardill1, Arwenna Davis1, Olamide Iyiola1 1 Macmillan Cancer Support P-42. Colorectal Cancer Outcomes – Comparing local data for the Taunton and Somerset NHS Foundation Trust with results reported in the National Bowel Cancer Audit Progress Report 2014 Helen Weaver1, Dylan Chew1, Adam Wood1, Louise Hunt1 1 Taunton and Somerset NHS Trust, Musgrove Park Hospital P-43. An Analysis of Unscheduled Care for Oncology Patients within a Regional Cancer Centre Peter Gallagher1, Nick Henry1, Debbie Wightman1, Paula Scullin1 1 Cancer Centre Belfast City Hospital, Belfast HSC Trust P-44. Improving Breast Services – it’s in the DNA Caroline Byrne1, Leena Chagla1 1 St Helens and Knowsley NHS Trust P-45. Mohs' Micrographic Surgery: A Needs Assessment of Patients with Basal Cell Carcinoma attending a large UK Health Care Trust Gemma McIntyre1, Louise MacDonald2, Olivia Dolan2, Olga Kerr1 1 Belfast City Hospital, 2Royal Victoria Hospital P-46. Coping with cancer - supporting young people's resilience Helen Gravestock1, Ruth Plackett1, Rachel Tappenden1, Tracy Cosgrave1 1 CLIC Sargent P-47. Rethinking Long Term Follow Up of Childhood Cancer Survivors in Northern Ireland Judith Ewing1 1 Public Health Agency P-48. Central Venous Access Devices in Childhood Cancers; Does site affect complication rate? A. E. Louise McMurran1, Atul Sabharwal1 1 Department of Paediatric Surgery, Royal Hospital for Sick Children, Glasgow P-49. Childhood Cancer Registry a Romanian initiative in order to ensure access to data of higher quality at national level. Daniela Coza1, 2, Luminita Blaga2, Alexandru Todescu3, Mihaela Bucurenci3, Monica Dragomir4 1 The Oncology Institute 'Prof. Dr. Ion Chiricuta', Cluj-Napoca, Romania, 2Cluj Regional Cancer Registry, 3Romanian Society of Pediatric Oncohematology, 4The Oncology Institute 'Prof. Dr. Alexandru Trestioreanu, 5The Oncology Institute 'Prof. Dr. Alexandru Trestioreanu 77 Posters P-50. Skin Cancer in under 18 years old in England Veronique Poirier1, Paul Losty2, Julia Verne1 1 Knowledge and Intelligence SW, PHE, 2University of Liverpool P-51. Cause-specific Late Mortality Among Survivors Of Childhood Cancer in Switzerland: a Population Based Cohort Study Matthias Schindler1, Corina S. Rueegg2, Ben D. Spycher1, Marc Ansari3, Roland A. Ammann4, Gisela Michel2, Claudia E. Kuehni1 1 Swiss Childhood Cancer Registry, University of Bern, 2Department of Health Sciences and Health Policy, University of Lucerne, 3Department of Pediatrics, Geneva University Hospital, 4Department of Pediatrics, University of Bern P-52. Loss in expectation of life due to a childhood cancer diagnosis; an example using CNS tumours Mark J Rutherford1, Raoul C Reulen2, David L Winter2, Paul C Lambert1,3, Michael M Hawkins2 1 Department of Health Sciences, University of Leicester, 2Centre for Childhood Cancer Survivor Studies, University of Birmingham, 3Department of Medical Epidemiology and Biostatistics, Karolinska Institutet P-53. Place of death for mortality aged under 25 years Shivaun Fleming1, Andy Pring1, Luke Hounsome1, Julia Verne1 1 Public Health England P-54. The Development of a Lifestyle Intervention for Teenage and Young Adult Cancer Survivors in the UK: Protocol Gemma Pugh1, Helen Gravestock2, Rachael Hough3, Wendy King3, Jane Wardle1, Abigail Fisher1 1 University College London, 2CLIC Sargent, 3University College London Hospitals P-55. Long-Term Renal Morbidity in Survivors of Childhood Cancer in the British Childhood Cancer Survivor Study (BCCSS) using data from the national Hospital Episode Statistics database. Kwok Wong1, Raoul Reulen1, Chloe Bright1, David Winter1, Joyeeta Guha1, Miranda Fidler1, Julie Kelly1, Clare Frobisher1, Rod Skinner2, Mike Hawkins1 1 The University of Birmingham, 2Newcastle University P-56. Cerebrovascular disease among 34, 489 five-year survivors of childhood cancer diganosed aged 0-14 years using Hospital Episode Statistics: The British Childhood Cancer Survivor Study Joyeeta Guha1, Raoul Reulen1, David Winter1, Julie Kelly1, Clare Frobisher1, Michael Hawkins1 1 Centre for Childhood Cancer Survivor Studies, University of Birmingham 78 Posters P-57. Cause- Specific mortality in 23,477 5-year survivors of central nervous system tumours diagnoesed under age 40 Chloe Bright1, Raoul Reulen1, Martin McCabe2, David Winter1, Mike Hawkins1 1 Centre for Childhood Cancer Survivor Studies, University of Birmingham, 2School of Cancer and Enabling Sciences, University of Manchester P-58. Improving data quality: children, teenagers and young adults data in the Systemic Anti-Cancer Therapies (SACT) dataset Michael Wallington1, Ralphael Oghagbon1, Wayne Brown1, Kellie Peters1 1 Public Health England P-59. Population-based long-term cardiac mortality among 34,489 5-year survivors of childhood cancer Miranda Fidler1, Raoul Reulen1, David Cutter2, Julie Kelly1, Clare Frobisher1, David Winter1, Michael Hawkins1 1 Centre for Childhood Cancer Survivor Studies, University of Birmingham, 2University of Oxford & Oxford Cancer and Haematology Centre P-60. Population-based long-term cause-specific mortality among 34,489 5-year survivors of childhood cancer Miranda Fidler1, Raoul Reulen1, Julie Kelly1, Clare Frobisher1, David Winter1, Michael Hawkins1 1 Centre for Childhood Cancer Survivor Studies, University of Birmingham P-61. Integration of Digital Pathology in Biobanking Quality Assurance and Biomarker Analysis Anne Carson1, Jacqueline James1, Stephen McQuaid1, Peter Bankhead1, Darragh McArt1, Manuel Salto-Tellez1, Peter Hamilton1 1 Queens University Belfast P-62. Audit of trial recruitment in Non-Hodgkins and Hodgkin lymphoma –Single centre Analysis. Isabella Lo1, Alison Milne1, Ania Pawlicka1 1 Basingstoke North Hampshire Hospital P-63. The Northern Ireland Biobank: Biomedical Scientist Role Christine Sterrett1, Edwina O'Doherty1, Stephen McQuaid1, Jacqueline James1 1 Northern Ireland Biobank, Molecular Pathology Programme, CCRCB, Queen’s University P-64. DNA and RNA quality control experiments of biobanked FFPE and fresh frozen tissue Edwina O'Doherty1, Christine Sterrett1, Stephen McQuaid1, Jacqueline James1 1 Northern Ireland Biobank, Molecular Pathology Programme, CCRCB, Queen’s University 79 Posters P-65. Northern Ireland Biobank (NIB) –A Nursing Perspective Paul Murray1, Adrina O'Donnell1 1 Queen University Belfast/Belfast Health and Social Care Trust P-66. A population level study of clinical trial participation among cancer patients in Northern Ireland Conan Donnelly1, Amy Wotherspoon2, Melanie Morris3, Richard Wilson4, Anna Gavin1 1 N. Ireland Cancer Registry, Centre for Public Health, Queen's University Belfast, 2 Centre for Public Health, Queen’s University Belfast, 3Belfast Health & Social Care Trust, 4Centre for Cancer Research and Cell Biology, Queen’s University Belfast P-67. Does weekly monitoring lead to improved performance? Daniel Hawksworth1 1 Scottish Government P-68. A cancer health intelligence hub for Wales – positive outcomes from data linkage Janet Warlow1, Ceri White1, Dyfed Huws1 1 Public Health Wales, Welsh Cancer Intelligence and Surveillance Unit P-69. Systemic Anti Cancer Therapy (SACT) dataset improvement and analysis in an integrated cancer system Stephen Scott1, Hilary Wilderspin1, Nisha Shaunak1, Jamie Ferguson1 1 London Cancer Alliance P-70. Building institutional capacity for increasing cancer data quality within Northwestern Regional Cancer Registry from Romania Luminita Blaga1,2, Alexandru Todescu1,2, Jan Nygård3, Daniela Coza1,2, Florian Nicula1, Anton Bereschi1,2, Elisabete Weiderpass3,4,5,6, Adela Moldovan1,2, Ciprian Turcu1,2, Patriciu Achimas-Cadariu1,7 1 The Oncology Institute “Prof. Dr. Ion Chiricuta”, 2Cluj Regional Cancer Registry, 3 Cancer Registry of Norway, 4Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 5Faculty of Health Sciences, The Arctic University of Norway, 6 Folkalsan Research Center, 7Iuliu Hatieganu University of Medicine and Pharmacy P-71. Using metrics to improve breast cancer services in London Stephen Scott1, Karen Linklater2 1 London Cancer Alliance, 2National Cancer Registration Service P-72. Improving the ascertainment and coding of Chronic Myeloid Leukaemia (CML) in England. CE Brook1, J Churchill1, SE Oliver2, R Ireland3 1 National Cancer Registration Service, Public Health England, 2Dept of Health Sciences University of York and Hull York Medical School, 3Dept of Haematology, King's College Hospital NHS Foundation Trust 80 Posters P-73. Building a pseudonymised, linked, cross-setting dataset covering Breast and Lung Cancer pathways in Manchester David Chapman1, George Ulmann1, Mike Standing1, Julie Flynn2, Nicola Cook2, Ashley Woolmore3 1 Monitor Deloitte, 2Macmillan Cancer Support, 3IMS Health P-74. The National Cancer Research Institute Clinical Studies Group portfolio triaging analysis: A tool to monitor funding and recruitment activity within the NCRI CSG portfolio Seema Alexander1, Michelle Cashin-Cox1, Eileen Loucaides1, Rachel Moser2, Matthew Seymour1,2 1 National Cancer Research Institute, 2National Institute for Health Research (NIHR) Clinical Research Network: Cancer P-75. The Mapping of datasets in the Cancer Analysis System (CAS) Christopher Lawrence1, John Broggio1, Matthew Francis1 1 Public Health England Knowledge and Intelligence Team West Midlands P-76. A Comprehensive Database System With High Resolution Pathology Data For Breast Cancer Screening - A Pilot Study Bogdan Fetica1, Carmen Lisencu1, Alexandru Eniu1, Daniela Coza1, Luminita Blaga1, Bogdan Pop1,2, Florian Nicula1, Patriciu Achimas-Cadariu1,2, Alexandru Irimie1,2, 1 The Oncology Institute “Prof. Dr. Ion Chiricuta”, 2Iuliu Hatieganu University of Medicine and Pharmacy P-77. Transformation of oncology nursing documentation Ben Wilson1, Olivia Samuel1, Katie Johns1, Jo Jackson1, Dan Tibble1, Jac Livsey1 1 The Christie NHS Foundation Trust P-78. Electronic Skin Cancer Reporting Michael Eden1, Veronique Poirier1 1 National Cancer Registration Service, Eastern Office P-79. The effect of deprivation on cancer incidence and mortality rates in the United Kingdom and the Republic of Ireland Eamonn O'Leary1 1 National Cancer Intelligence Network P-80. Factors associated with Palliative Outcomes among cancer patients in a UK region Victoria Cairnduff1, Conan Donnelly1, Finian Bannon1, Deirdre Fitzpatrick1, Barbara Gomes2, Anna Gavin1 1 N. Ireland Cancer Registry, Centre for Public Health, Queen’s University Belfast, 2 Cicely Saunders Institute of Palliative Care, Policy & Rehabilitation, King’s College London 81 Posters P-81. Factors associated with terminally-ill cancer patients achieving their preference to die at home. Finian Bannon1, Deirdre Fitzpatrick1, Janine Blaney0, Conan Donnelly1, Barbara Gomes3, Anna Gavin1 1 N. Ireland Cancer Registry, Centre for Public Health, Queen's University Belfast, 2 Belfast Trust, 3Cicely Saunders Institute of Palliative Care, King’s College P-82. HPV prevalence and type-distribution in cervical cancer and premalignant lesions of the cervix: a population-based study from Northern Ireland. Michael O'Rorke1, Lesley Anderson1, Robbie Wilson2, Jackie Jamison2, Anna Gavin3 1 Centre for Public Health, Queen's University Belfast., 2Cellular & Molecular Pathology, Northern Health & Social Care Trust, 3 N. Ireland Cancer Registry, Centre for Public Health, Queen's University Belfast P-83. Statin use after diagnosis of breast cancer and survival: a population-based cohort study. Chris Cardwell1, Blanaid Hicks1, Carmel Hughes2, Liam Murray1 1 Centre for Public Health, Queen's University Belfast, 2School of Pharmacy, Queen's University Belfast P-84. Hospital outpatient attendances linked to cancer registrations in England: Analysis of peri-diagnostic period Sarah Miller1, Sean McPhail2, Jonathan Shelton2, Lucy Irvine2, Mick Peake2 1 Knowledge & Intelligence Team (East), Public Health England, 2National Cancer Intelligence Network, Public Health England P-85. Does the route in which the diagnosis of pancreatic cancer is made affect the likelihood of surgery and survival? Victoria H Coupland1, Niteen Tapuria2, William Allum 2, Daniela Tataru1, Margreet Lüchtenborg1,3, Ruth H Jack1 1 Public Health England, 2The Royal Marsden NHS Foundation Trust, 3King's College London P-86. Tobacco smoking and survival after prostate cancer Antonella Zucchetto1, Jerry Polesel1, Andrea Gini1, Luigino Dal Maso1, Carmen Stocco2, Silvia Birri1, Ettore Bidoli1, Diego Serraino1 1 CRO Aviano National Cancer Institute, 2Istituto Oncologico Veneto P-87. Establishing a population-based register of monoclonal gammopathy of undetermined significance (MGUS) in Northern Ireland Charlene M. McShane1, Liam J. Murray1, Anna T. Gavin2, Eve Roman3, Han-I Wang3, Lesley A. Anderson1 1 Centre for Public Health, Queen's University Belfast, 2 N. Ireland Cancer Registry, Centre for Public Health, Queen's University Belfast, 3Epidemiology and statistics research group, University of York 82 Posters P-88. Examining methods to visualise the cancer population using cartograms Samuel Jones1, Hannah McConnell1, Ceri White2, Dyfed Huws2, Lucy Irvine3, Sarah Miller4 1 Macmillan Cancer Support, 2Public Health Wales, Welsh Cancer Intelligence and Surveillance Unit, 3Public Health England, National Cancer Intelligence Network, 4 Public Health England, Knowledge and Intelligence Team (East) P-89. Cancer Incidence Projections to 2035 in Northern Ireland Anna Gavin1, David Donnelly1 1 N. Ireland Cancer Registry, Centre for Public Health, Queen's University Belfast P-90. Better lung cancer stage distribution in more deprived areas of Wales offset by much worse stage 1 and 2 one year survival Ceri White1, Rebecca Thomas1, Julie Howe1, Tamsin Long1, Ciaran Slyne1, Dyfed Huws1 1 Welsh Cancer Intelligence and Surveillance Unit P-91. Barriers to early presentation with, and diagnosis of, symptomatic breast cancer across the UK: A qualitative study comparing Black African, Black Caribbean and White women Emma Ream 1, Claire Jones2, Grace Lucas3, Elizabeth Davies2, Ruth Jack4, Jill Maben2 1 University of Surrey, 2King's College London, 3The Royal Marsden NHS Foundation Trust, 4Public Health England P-92. Using the ‘Routes from Diagnosis’ framework to understand variations in survivorship outcomes for Breast Cancer in the City of Manchester David Chapman1, George Ulmann1, Mike Standing1, Julie Flynn2, Nicola Cook2, Ashley Woolmore3, Wendy Makin4, Nigel Bunfred5 1 Monitor Deloitte, 2Macmillan Cancer Support, 3IMS Health, 4The Christie Hospital NHS FT, 5University Hospital of South Manchester NHS FT P-93. Using the ‘Routes from Diagnosis’ framework to understand variations in survivorship outcomes for Lung Cancer in the City of Manchester David Chapman1, George Ulmann1, Mike Standing1, Julie Flynn2, Nicola Cook2, Ashley Woolmore3, Wendy Makin4, Philip Barber5 1 Monitor Deloitte, 2Macmillan Cancer Support, 3IMS Health, 4The Christie Hospital NHS FT, 5University Hospital of South Manchester NHS FT P-94. Are women with cervical cancer, diagnosed at the same stage of disease, treated differently according to age, deprivation or region? Jennifer Lai1, Rebecca Elleray1, Jason Poole1 1 Public Health England, Knowledge and Intelligence P-95. Issues needs and concerns of women with Breast Cancer in rural Scotland Karen Scanlon1, Gill Hubbard2, Richard Kyle3, Christine Venning1, Alison Walker1, Emma Lavelle1 1 Breast Cancer Care, 2University of Stirling, 3Edinburgh Napier University 83 Posters P-96. Comparing South Island NZ Chemotherapy Data using the Systemic AntiCancer Therapy Dataset (SACT) Di Riley1, Shaun Costello1, Ursula Jewell1, Sarah Tomlinson2, Drew Winter3, Chris Jackson2 1 Southern Cancer Network, 2University of Otago, 3Canterbury District Health Board P-97. Role of treatment in international differences in one-year mortality from early stage non-small cell lung cancer: a tentative answer from the International Cancer Benchmarking Partnership study Tsion Solomon1, Michael Peake2, John Butler3, Michel Coleman4, William Evans5, Erik Jakobsen6, Michael Boyer7, Tom Børge Johannesen8, Bernard Rachet9 1 Cancer Survival Group, London School of Hygiene & Tropical Medicine, 2Department of Respiratory Medicine, Glenfield Hospital, 3Royal Marsden Hospital, 4Cancer Survival Group, London School of Hygiene & Tropical Medicine, 5Juravinski Cancer Centre at Hamilton Health Sciences, Cancer Care Ontario, 6Odense University Hospital, 7Department of Medical Oncology, Royal Prince Alfred Hospital, 8Norwegian Cancer Registry, 9Cancer Survival Group, London School of Hygiene & Tropical Medicine P-98. Morbidity and Mortality in Gynaecological Oncology Thumuluru Kavitha Madhuri1,2, Simon Butler-Manuel1, Sarada Kannangara1, Patricia Ellis1, Anil Tailor1 1 Royal Surrey County Hospital NHS Foundation Trust, 2University of Surrey P-99. James Lind Alliance (JLA) neuro-oncology priority setting partnership (PSP): Process to identify the top 10 UK priorities for clinical research Helen Bulbeck1, Robin Grant2, Julia Day3, Lucy Macdonald4, Richard Morley5, Gail Quinn6, Kathy Oliver7 1 Brainstrust,, 2Department of Clinical Sciences, Western General Hospital,, 3NHS Lothian, 4NHS Lothian, 5James Lind Alliance (JLA), 6Cochrane Collaboration, 7 International Brain Tumour Alliance (IBTA) P-100. Retroperitoneal sarcoma long term outcomes Matthew Francis1, Nicola Dennis1, John Broggio1, Dirk Strauss2 1 Public Health England Knowledge & Intelligence Team West Midlands, 2The Royal Marsden NHS Foundation Trust P-101. A landmark programme to understand the needs and experiences of all people affected by blood cancer Lauren Dias1, David Henderson1 1 Leukaemia & Lymphoma Research, Holborn P-102. Designing specialist services for cancer of unknown primary in the West of Scotland. Gwen Allardice1, David Morrison1, William Jones2 1 West of Scotland Cancer Surveillance Unit, 2University of Glasgow 84 Posters P-103. Review of establishing a Cancer of unknown primary two week wait GP referral service at University Hospitals Bristol NHS Foundation Trust Joanita Ocen1, Anna Kuchel1 1 Bristol Cancer Institute P-104. Long-term cardiac morbidity among 5-year survivors of childhood cancer Miranda Fidler1, Raoul Reulen1, Chloe Bright1, Katherine Henson1, Joyeeta Guha1, Kwok Wong1, Julie Kelly1, Clare Frobisher1, David Winter1, Michael Hawkins1 1 Centre for Childhood Cancer Survivor Studies, University of Birmingham P-105. Bridging The Age Gap in Breast Cancer - improving treatment decisions for older women using routine data Paul Richards1, Sue Ward1, Jenna Morgan2, Matthew Francis3, Karen Collins4, Maria Burton4, Ant Nettleship5, Katherine Lifford6, Malcolm Reed7, Lynda Wyld2 1 School of Health and Related Research, The University of Sheffield, 2Deparment of Oncology, The University of Sheffield, 3Public Health England, Knowledge and Information Team (West Mids), 4Centre for Health and Social Care Research, Sheffield Hallam University, 5EpiGenesys, The University of Sheffield, 6Institute of Primary Care and Public Health, Cardiff University, 7Brighton and Sussex Medical School P-106. Understanding areas of need and patient experience in older patients with blood cancer Lauren Dias1, David Henderson1 1 Leukaemia & Lymphoma Research, Holborn P-107. Impact of patient’s age on treatment and outcome in diffuse large B-cell lymphoma (DLBCL): an analyses from the UK’s population-based Haematological Malignancy Research Network Alexandra Smith1, Eve Roman1, Debra Howell1, Russell Patmore2 1 University of York, 2Hull and East Yorkshire Hospitals NHS Trust P-108. Older people and cancer in England – pulling together the evidence Lucy Irvine1, Sean Duffy2, Mike Birtwistle3, Laura Harper2, Hannah McConnell4, Selina Mehra4, Nick Ormiston-Smith5, Katrina Brown5, Jodie Moffat5, Lucy Elliss-Brookes1 1 PHE National Cancer Intelligence Network (NCIN), 2NHS England, 3Incisive Health, 4 Macmillan Cancer Support, 5Cancer Research UK P-109. Radiotherapy Patient Experience Survey – NHSScotland results Scott Taylor1, Fiona Hodgkiss1 1 Scottish Government P-110. A methodological review of the Short Form Health Survey 36 (SF-36) and its derivatives among breast cancer survivors Charlene Treanor1, Michael Donnelly1,2 1 Centre for Public Health, Queen's University Belfast, 2UKCRC Centre of Excellence for Public Health, Queen's University Belfast 85 Posters P-111. The people behind cancer care: Understanding the link between patient and staff experiences Anna Chourdaki1, Hannah McConnell1 1 Macmillan Cancer Support P-112. Analysis of National Cancer Patient Experience Survey Stephen Scott1, Hilary Wilderspin1 1 London Cancer Alliance P-113. The Cancer Patient Portal: First steps towards record access for all cancer patients Michael Chapman1, Julie Temple1, Ruth Stafferton1, Will Jones2, Sarah Stevens3 1 Cancer Research UK, 2Brainstrust, 3Public Health England P-114. Myeloproliferative neoplasm patients experience significant symptom burden. Lesley Anderson1, Glen Titmarsh1, Mary Frances McMullin2, Andrew Duncombe3, Ruben Mesa4, Robyn Scherber4, Amylou Dueck4, Frank DeVocht5, Lin Fritschi6, Mike Clarke1 1 Centre for Public Health, Queen’s University Belfast, 2Centre for Cancer Research and Cell Biology, Queen’s University Belfast, 3Department of Haematology, University Hospitals Southampton NHS Foundation Trust, 4Mayo Clinic Cancer Centre, 5 University of Bristol, 6Curtin University P-115. Life After Prostate Cancer Diagnosis (LAPCD) Amy Downing1, Penny Wright1, Richard Wagland2, Eila Watson3, Hugh Butcher4, Luke Hounsome5, Conan Donnelly6, Therese Kearney6, Rebecca Mottram1, Majorie Allen1 1 University of Leeds, 2University of Southampton, 3Oxford Brookes University, 4User representative, 5South West Knowledge & Intelligence Team, Public Health England, 6 N. Ireland Cancer Registry, Centre for Public Health, Queen's University Belfast P-116. Exploration and analysis of free-text responses from the 2013 Wales Cancer Patient Experience Survey (WCPES) Richard Wagland1, Michael Bracher1, Jessica Corner1 1 Faculty of Health Sciences, University of Southampton P-117. Living with and beyond gynaecological cancer: descriptive summary of the gynaecological cancer PROMs pilot survey Matthew Barclay1, Nick Wood2, Anne Lanceley3, Jason Poole1, Jo Partington4, Maureen Dowling4, Andrew Nordin5 1 Public Health England, 2Lancashire Teaching Hospitals NHS Foundation Trust, 3 University College London, 4NHS England, 5East Kent Hospitals University Foundation Trust P-118. Understanding greatest areas of patient need throughout the blood cancer journey Lauren Dias1, David Henderson1 1 Leukaemia & Lymphoma Research, Holborn 86 Posters P-119. Prevalence and predictors of procedure-related distress in men undergoing prostate biopsy Eileen Morgan1, Frances J Drummond2, Finian Bannon1, Heather Kinnear1, Anna Gavin1, Linda Sharp2,3 1 N. Ireland Cancer Registry, Centre for Public Health, Queen's University Belfast, 2 National Cancer Registry, 3Newcastle University P-120. Inclusion of a lottery scratch card was more effective than entry into a prize draw in increasing questionnaire response among prostate cancer survivors, identified from cancer registries Frances Drummond1, Eamonn O'Leary1, Linda Sharp1 1 National Cancer Registry Ireland P-121. Challenges of establishing a population-based patient-reported outcomes study (PROMs) using national cancer registries across two jurisdictions; The Prostate Cancer Treatment, your experience (PiCTure) Study Frances Drummond1, Heather Kinnear2, Conan Donnelly2, Eamonn O'Leary1, Katie O'Brien1, Richeal Burns3, Anna Gavin2, Linda Sharp1 1 National Cancer Registry Ireland, 2 N. Ireland Cancer Registry, Centre for Public Health, Queen's University Belfast, 3National University of Ireland, Galway P-122. Keeping The Customer Satisfied #1: Is Taking Part in Research Associated With Better Experience of Care? Findings from the 2013 National Cancer Patient Experience Survey Richard Stephens1, Carolyn Morris1, Robert West2, Matthew Baker1, Ekaterini Blaveri3, Rachel Brannen3, Sheila Fisher5, Jane Hanson4, Sue Pavitt2, Reg Race6 1 NCRI Consumer Liaison Group, 2Leeds Institute of Health Sciences, University of Leeds, 3National Cancer Intelligence Network, 4NIHR Local Clinical Research Network : Kent Surrey Sussex, 5NIHR Clinical Research Network Cancer, 6Quality Health P-123. Keeping The Customer Satisfied #2 It Is OK To Ask – Who Are We Asking, And Who Participates? Further Findings from the National Cancer Patient Experience Survey 2013 Richard Stephens1, Carolyn Morris1, Robert West2, Matthew Baker1, Ekaterini Blaveri3, Rachel Brannen3, Sheila Fisher5, Jane Hanson4, Sue Pavitt2, Reg Race6 1 NCRI Consumer Liaison Group, 2Leeds Institute of Health Sciences, University of Leeds, 3National Cancer Intelligence Network, 4NIHR Local Clinical Research Network : Kent Surrey Sussex, 5NIHR Clinical Research Network Cancer, 6Quality Health 87 Posters P-124. Keeping the Customer Satisfied #3 It's OK To Ask - Who Are We Asking? Variations by Type of Cancer Further Findings from the National Cancer Patient Experience Survey Richard Stephens1, Carolyn Morris1, Robert West2, Matthew Baker1, Ekaterini Blaveri3, Rachal Brannen3, Sheila Fisher5, Jane Hanson4, Pavitt Sue2, Reg Race6 1 NCRI Consumer Liaison Group, 2Leeds Institute of Health Sciences, University of Leeds, 3National Cancer Intelligence Network, 4NIHR Local Clinical Research Network : Kent Surrey Sussex, 5NIHR Clinical Research Network Cancer, 6Quality Health P-125. Keeping The Customer Satisfied #4 - We Need To Talk! Responses From Patients To Questions On Research In The National Cancer Patient Experience Survey 2014 Richard Stephens1, Carolyn Morris1, Robert West2, Matthew Baker1, Sheila Fisher3, Jane Hanson4, Sue Pavitt2, Karen Inns3 1 NCRI Consumer Liaison Group, 2Leeds Institute of Health Sciences, University of Leeds, 3NIHR Clinical Research Network Cancer, 4NIHR Local Clinical Research Network : Kent Surrey Sussex P-126. Do men regret undergoing a diagnostic prostate biopsy? Catherine Coyle1, Finian Bannon2, Eileen Morgan2, Frances Drummond3, Linda Sharp3, Anna Gavin2 1 Public Health Agency, 2 N. Ireland Cancer Registry, Centre for Public Health, Queen's University Belfast, 3National Cancer Registry Ireland P-127. Physical side-effects in men undergoing prostate biopsy: an all-Ireland study Anna Gavin1, Eileen Morgan1, Frances Drummond2, Catherine Coyle3, Linda Sharp2,4 1 N. Ireland Cancer Registry, Centre for Public Health, Queen's University Belfast, 2 National Cancer Registry of Ireland, 3Public Health Agency, 4Recently moved to Institute of Health and Society, Newcastle University P-128. Emergency Colorectal Cancer Presentations: Can they be prevented in Primary Care? Jennie Grainger1, Zaid Hamoodi1, Hayley Fowler1, Raj Rajaganeshan1 1 St Helens. And Knowsley NHS Trust P-129. Exploring the potential to link primary care data with the national cancer registry of the Welsh Cancer Intelligence and Surveillance Unit Christopher Johnson1, Janet Warlow2, Ceri White2, Dyfed Wyn Huws2 1 Public Health Wales, 2Welsh Cancer Intelligence and Surveillance Unit, Public Health Wales P-130. How can primary care be better involved in initiatives to improve uptake of cancer screening programmes? David Linden1,2 1 Scottish Government, 2Macmillan Cancer Support 88 Posters P-131. Trends in usage of the urgent GP referrals for suspected cancer system Matthew Barclay1, Carolynn Gildea1, David Meechan1 1 Public Health England P-132. General Practice Profiles for Cancer: How variable are the practices and can we reliably judge their diagnostic performance? Gary Abel1, Catherine Saunders0, Georgios Lyratzopoulos1,3 1 Cambridge Centre for Health Services Research, University of Cambridge, UK, 2 RAND Europe, 3Health Behaviour Research Centre, University College London P-133. A preliminary examination of linked data from the West Midlands breast cancer registry, breast screening programme and primary care. Melanie Morris1, Bernard Rachet1, Laura Woods1 1 London School of Hygiene and Tropical Medicine P-134. Surviving small cell lung cancer in three countries - an international comparison Christine Park2, Gwen Allardice1, David Morrison1 1 West of Scotland cancer surveillance unit, 2University of Glasgow P-135. Outcome of critically ill patients with solid malignancies admitted by oncology to the intensive care unit at The Royal Free Hospital (London) between 2009 and 2014 Yanrong (Yani) Jiang1, Robert Goldstein2, Christina Thirlwell2, Astrid Meyer2, Tim Meyer2, Roopinder Gillmore2 1 University College London Medical School, 2Royal Free Hospital P-136. The Impact of the Glasgow Improving The Cancer Journey Service Sandra McDermott1 1 Glasgow City Council P-137. Late effects of cancer and cancer treatment- the patient’s perspective Charlene Treanor1, Michael Donnelly1,2 1 Centre for Public Health, Queen's University Belfast, 2UKCRC Centre of Excellence for Public Health, Queen's University Belfast P-138. Action Cancer's Positive Living Programme: a therapeutic application of coaching. Caroline Hughes1, Geraldine Kerr1, Mary Morrow1, Karen Clarke1, Ruth Fleming1 1 Action Cancer P-139. Using Electronic Holistic Needs Assessment (eHNA) data to explore the needs of people with cancer and how they are addressed Kinga Kuczkowska1, Amanda Watson1, Andrew Brittle1 1 Macmillan Cancer Support 89 Posters P-140. Trajectories of quality of life, health and personal wellbeing up to two years following curative intent treatment for colorectal cancer: results from the UK ColoREctal Wellbeing (CREW) cohort study Claire Foster1, Joanne Havliand1, Chloe Grimmett1, Jane Winter1, Deborah Fenion1, Kimberly Chivers Seymour1, Christine M May1, Peter W Smith2, Jessica Corner1, Alison Richardson1 1 University of Southampton Faculty of Health Sciences, 2University of Southampton, Southampton Statistical Sciences Research Institute P-141. Bladder cancer recurrence; evidence of wide variation in England Roger Kockelbergh1, Erik Mayer2, Luke Hounsome3, Julia Verne3 1 University Hospitals Leicester NHS Trust, 2Imperial College Healthcare NHS Trust, 3 Public Health England, Knowledge and Intelligence Team (South West) P-142. Understanding the practical, personal and emotional support needs of people living with cancer in the UK – during treatment, survivorship, and end of life Clara Miglio1, Rachel Bowden1, Claire Burley1, Fiona Smith1 1 Macmillan Cancer Support P-143. A Systematic Review of Serum Adiponectin and Leptin and Breast Cancer Progression Suping Ling1, Roisin O'Neill1, Liam Murray1, Marie Cantwell1 1 Centre for Public Health, Queen's University Belfast P-144. Understanding the needs of blood cancer patients post treatment Lauren Dias1, David Henderson1 1 Leukaemia & Lymphoma Research, Holborn P-145. RESTORE: supporting self-management of cancer-related fatigue, an exploratory randomised controlled trial of a web-based intervention. Claire Foster1, Chloe Grimmett1, Christine M May1, Sean M Ewings2, Lynn Calman1, Jo Armes3, Carl May1, Emma Ream 4, Lucy Yardley5, Alison Richardson1 1 University of Southampton Faculty of Health Sciences, 2University of Southampton, Southampton Statistical Sciences Research Institute, 3Kings College London, 4 University of Surrey School of Health Sciences, 5University of Southampton School of Psychology P-146. Changes in the Death Causes of Adult Cancer Survivors According to their Survival Period. MINKYUNG JO1, Young Ae Kim 2, Duk Hyoung Lee2, Eun Sook Lee1 1 Research Institute, National Cancer Center, 2National Cancer Control Institute, National Cancer Center P-147. Psychosocial interventions for informal caregivers of people living with cancer Olinda Santin1, Gillian Prue1, Helen Coleman1, Chris Cardwell1, Peter O Halloron1, Michael Donnelly1 1 Queens University Belfast 90 Posters P-148. A new way of counting cancer prevalence to understand the prevalence of multiple primaries in the UK Samuel Jones1, Hannah McConnell1, Ceri White2, Dyfed Huws2, Lucy Irvine3, Sarah Miller4 1 Macmillan Cancer Support, 2Public Health Wales, Welsh Cancer Intelligence and Surveillance Unit, 3Public Health England, National Cancer Intelligence Network, 4 Public Health England, Knowledge and Intelligence Team (East) P-149. 20-year cancer prevalence in the UK by cancer type: exploring variations between short-term and long-term survivors in the cancer population Samuel Jones1, Hannah McConnell1, Ceri White2, Dyfed Huws2, Lucy Irvine3, Sarah Miller4 1 Macmillan Cancer Support, 2Public Health Wales, Welsh Cancer Intelligence and Surveillance Unit, 3Public Health England, National Cancer Intelligence Network, 4 Public Health England, Knowledge and Intelligence Team (East) P-150. Transforming Care After Treatment –Influencing Redesign By Service Users Gordon McLean1 1 Macmilan Cancer Support P-151. Implementing an innovative survivorship navigator role to deliver the recovery package to men in Havering living with the consequences of prostate cancer. Sharon Cavanagh1, Lucy Brooks2 1 London Cancer, 2Barking Havering and Redbridge University Hospitals Trust P-152. Shoulder-to-shoulder support: using walking interviews to understand the significance of a peer-led walking group intervention for breast cancer survivors Karen Scanlon1, Richard Kyle2, Aileen Ireland3, Jennifer Finnegan-John1, Leanne Taylor-Sturdy1, Claire Knight1, Emma Lavelle1 1 Breast Cancer Care, 2Edinburgh Napier University, 3University of Stirling P-153. Is England closing the international gap in cancer survival? Muller Patrick1, Walters S1, Benitez-Majano S1 1 Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine P-154. The effect of warfarin therapy on breast, colorectal, lung and prostate cancer survival: a population based cohort study using the Clinical Practice Research Datalink. Michael O'Rorke1, Liam Murray1, Carmel Hughes2, Marie Cantwell1, Chris Cardwell1 1 Centre for Public Health, Queen's University Belfast, 2School of Pharmacy, Queen's University Belfast. 91 Posters P-155. Improving access to curative therapies in lung cancer for Northern Ireland Jonathan McAleese1, Wendy Anderson2, Darren Brady1, Lisa Ranaghan4 1 Northern Ireland Cancer Centre, Belfast City Hospital, 2Antrim Area Hospital, Antrim, 3 Northern Ireland Cancer Centre, Belfast City Hospital, 4Northern Ireland Cancer Registry P-156. Access to Sentinel Lymph Node Biopsy for Malignant Melanoma Patients in England Veronique Poirier1, Isobel Tudge1, Luke Hounsome1, Jackie Charman2, Julia Verne1 1 Knowledge and Intelligence Team SW, PHE, 2Knowledge and Intelligence Team WM, PHE P-157. Induction chemotherapy and surgery for non-small cell lung cancer (NSCLC): challenging current thinking Ruth Johnston1, Jonathan McAleese1, Kieran McManus2 1 Cancer Centre, Belfast City Hospital, 2Department of Thoracic Surgery, Royal Victoria Hospital P-158. The surgical management of isolated paraaortic lymph node recurrence following colorectal cancer resection: A case series and systematic review Elaine Burns1,2, Amir Ardakani1, Alex Loh1, Rob Glynne-Jones1,3, Colin Elton1 1 Barnet Hospital, Royal Free NHS Foundation Trust, 2Imperial College London, 3 Mount Vernon Cancer Centre, Mount Vernon Hospital P-159. Breast cancer risk following treatment of screen-detected ductal carcinoma insitu: a population-based data linkage study Buckley Elizabeth1, Sullivan T1, Hiller J1, Farshid G1, Roder David1 1 School of Population Health, University of South Australia P-160. Rarer cancer patients and the importance of collaboration Dawn Green P-161. Variations in usage of the urgent GP referrals for suspected cancer system in general practice Carolynn Gildea1, Matthew Barclay1, David Meechan1 1 Public Health England P-162. Two regional pilot “Be Clear on Cancer” awareness campaigns – How does their impact compare? Assessment of the impact on urgent GP referrals for suspected cancer. Matthew Barclay1, Carolynn Gildea1, Alexandra Thackeray1 1 Public Health England P-163. Breast cancer in women over 70 “Be Clear on Cancer” awareness - What impact did it have on urgent GP referrals for suspected cancer? Carolynn Gildea1, Sue Wild1, Matthew Barclay1, Alexandra Thackeray1 1 Public Health England 92 Posters P-164. The role of cyclooxygenase-2 expression in stage II and stage III colon cancer survival. Ronan Gray1, Marie Cantwell1, Helen Coleman1, Maurice Loughrey2,4, Chris Cardwell1, Jacqueline James2,3,4, Stephen McQuaid2,3, Manuel Salto-Tellez2,4, Liam Murray1, 1 Centre for Public Health, Queen's University Belfast, 2Centre for Cancer Research and Cell Biology, Queen's University Belfast, 3Northern Ireland Biobank, Queen's University Belfast, 4Department of Pathology, Belfast Health and Social Care Trust P-165. A better strategy for patient involvement is needed Sarah Thornton, David Dodwell P-166. Life After Prostate Cancer Diagnosis (LAPCD): A user Advisory Group perspective Hugh Butcher 93 Notes 94 Notes 95 Notes 96 Notes 97 Notes 98 PROGRAMME AT A GLANCE DAY ONE – MONDAY 8 JUNE Grand Ballroom Conference Registration, Posters & Exhibition Viewing 11:00 – 12:30 Exhibition Centre Welcome & Plenary Session 1: Changing clinical practice: Importance of routine data and cancer registries 12:30 – 13:50 13:15 – 13:30 Grand Ballroom Dublin 1&2 Lunch - Exhibition & Poster Viewing Cancer Patient Portal demonstration 13:50 – 15:20 Session 1 Session 2 Session 3 15:20 – 15:50 Exhibition Centre Penthouse Suite Dublin 1&2 Grand Ballroom Parallel Sessions Early Diagnosis of Cancer Data Processing, Management & National SACT data Treatments Refreshments, Exhibition & Poster Viewing 15:50 – 17:20 Exhibition Centre DAY TWO – TUESDAY 9 JUNE Plenary Session 2: Role of Primary Care in Cancer Prevention, Screening and Early Diagnosis 08:00 – 08:45 Grand Ballroom Conference Registration, Exhibition & Poster Viewing 08:45 – 10:30 Exhibition Centre Plenary Session 3: International issues in cancer 10:30 – 11:00 Grand Ballroom Refreshments, Exhibition & Poster Viewing Exhibition Centre Penthouse Suite Dublin 1&2 Grand Ballroom Library Bar Parallel Sessions Changing Clinical Practice Prevention Childhood, Teenage & Young Adults Lunch - Exhibition & Poster Viewing CRUK Dragon’s Den (pre-booking required) 14:00 – 15:30 Session 7 Session 8 Session 9 15:30 – 16:00 Dublin 1&2 Exhibition Centre Penthouse Suite Grand Ballroom Parallel Sessions Site Specific Clinical Reference Group– Urology Cancers Survivorship Epidemiology/Clinical trials Refreshments, Exhibition & Poster Viewing 16:00 – 17:30 Exhibition Centre 11:00 – 12:30 Session 4 Session 5 Session 6 12:30 – 14:00 Plenary Session 4: Childhood, Teenage and Young Adult Cancers, Beyond Cancer Survival National Cancer Intelligence Network Cancer Outcomes Conference 2015 National Cancer Intelligence Network : Cancer Outcomes Conference 2015 09:30 – 11:00 Carrick-a-Rede Rope Bridge City Hall Giant’s Causeway DAY THREE – WEDNESDAY 10 JUNE 08:30 – 09:30 Grand Ballroom Library Bar Conference Registration, Exhibition & Viewing Poster Finalists AGM of UK & Ireland Association of Cancer Registries 09:30 – 11:00 Session 10 Session 11 Session 12 11:00 – 11:30 Dublin 1&2 Penthouse Suite Exhibition Centre Grand Ballroom Parallel Sessions Pharmaco-Epidemiology Health Economics Inequalities Refreshments, Exhibition & Viewing Poster Finalists 11:30 – 12:40 Exhibition Centre Plenary Session 5: Panel Debate: Future challenges for cancer services 12:40 – 13:00 Exhibition Centre Poster Prizes & Close of Conference 13:00 – 14:00 Grand Ballroom Lunch (packed lunch available on request, must be pre-booked) 8-10 June | Europa Hotel, Belfast
